Aryl indazole ring compound, preparation method, pharmaceutical composition and application

By developing aryl indazole cyclic compounds as VEGFR2 inhibitors, the side effects of existing VEGFR2 inhibitors in clinical applications have been solved, effective prevention and treatment of rheumatoid arthritis has been achieved, and good metabolic stability has been demonstrated. and pharmacological activity.

CN118994101AActive Publication Date: 2024-11-22ANHUI MEDICAL UNIV
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
CN202411082106.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-08
Publication Date
2024-11-22
Estimated Expiration
2044-08-08

AI Technical Summary

Technical Problem

The existing VEGFR2 inhibitors have adverse side effects in clinical applications and are difficult to effectively inhibit rheumatoid arthritis, resulting in a lack of safe and efficient drugs on the market to prevent and treat the disease.

Method used

An aryl indazole cyclic compound was developed, prepared by specific synthetic methods. As a VEGFR2 inhibitor, it can effectively inhibit the phosphorylation of the VEGFR2 tyrosine kinase domain, thereby regulating the function of vascular endothelial cells, and for prevention or Treatment of rheumatoid arthritis.

Benefits of technology

This compound showed good preventive or therapeutic effects in in vitro experiments, has significant inhibitory effects on the VEGFR2/PI3K/AKT pathway, has good metabolic stability and pharmacological activity, and provides a new treatment for rheumatoid arthritis strategy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118994101A_ABST
    Figure CN118994101A_ABST
Patent Text Reader

Abstract

The invention relates to an aryl indazole ring compound, a preparation method, a pharmaceutical composition and application. The aryl indazole ring compound comprises a compound shown in a formula (I) or pharmaceutically acceptable salt thereof. The invention also relates to a pharmaceutical composition containing the aryl indazole ring compound, a preparation method of the aryl indazole ring compound and application of the aryl indazole ring compound and the pharmaceutical composition to preparation of drugs for preventing or treating rheumatoid arthritis diseases, and the aryl indazole ring compound and the pharmaceutical composition have good prevention or treatment effects and certain druggability and can be used for preparing drugs for preventing or treating rheumatoid arthritis diseases. In an in-vitro experiment, VEGFR2 tyrosine kinase structural domain phosphorylated Tyr951 is combined with a t cell specific adapter under an anoxic condition to trigger activation of VEGFR2 signal transduction downstream PI3K / AKT so as to regulate functions of vascular endothelial cells, the chemical structure of the aryl indazole ring compound disclosed by the invention is different from that of an existing VEGFR2 inhibitor, and the aryl indazole ring compound can be used for preparing a medicine for treating vascular endothelial cells. The compound is a VEGFR2 inhibitor with a brand new structure, and has good metabolic stability. # imgabs0 #
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the technical field of pharmaceutical chemistry and pharmacotherapy, and in particular relates to an aryl indazole ring compound, a preparation method, a pharmaceutical composition and use thereof. Background Art

[0002] Synovial angiogenesis is the key to synovial expansion, proliferation and infiltration, and also contributes to rheumatoid arthritis inflammation and cartilage / bone damage. According to statistics, the incidence of rheumatoid arthritis is 0.5%-1.0%, and the majority of patients are women. Due to its long course, high disability rate and wide incidence, it has caused serious social and public health problems. VEGFR2, also known as fetal liver kinase-1 (Flk-1) in mice and kinase insert domain receptor (KDR) in humans, is the main mediator of angiogenesis, mitosis and vascular permeability activity. Neoangiogenesis refers to the process of forming new blood vessels from pre-existing capillaries in a sprouting manner. This process is involved in many physiological and pathological processes in the human body, including but not limited to embryonic development, menstrual cycle, wound healing, as well as tumors, rheumatoid arthritis, diabetes and retinopathy. Therefore, VEGFR2 has significant significance for the physiological process of angiogenesis and may be helpful for future anti-tumor therapy or the treatment of rheumatic diseases such as rheumatoid arthritis and autoimmune diseases.

[0003] KDR expression increases during hypoxia and is a key inducer of VEGF gene transcription. Increased VEGF / KDR signaling not only promotes angiogenesis but also plays a key role in atherosclerosis and chronic inflammation. Phosphorylation of Tyr951 in the tyrosine kinase domain of VEGFR2 binds to the T-cell-specific adaptor, triggering the activation of PI3K / AKT downstream of VEGFR2 signaling, thereby regulating the function of vascular endothelial cells. Therefore, targeting the VEGFR2 / PI3K / AKT pathway to inhibit synovial angiogenesis is a reasonable strategy for the treatment of rheumatoid arthritis.

[0004] The growth and maturation of new blood vessels requires stimulation by multiple growth factors; however, vascular endothelial growth factor (VEGF) signaling is often the key rate-limiting step in physiological and pathological angiogenesis. VEGFR2 is a major mediator of mitosis, angiogenesis, microvascular permeability, and survival of endothelial cells. Therefore, direct inhibition of signal transduction through the VEGF / VEGFR2 system is a promising strategy to inhibit angiogenesis. Since the formation of new blood is crucial in RA, direct inhibition of VEGFR2 kinase activity is expected to reduce angiogenesis, which may provide a promising strategy for RA treatment. In addition, reports of several VEGFR2 inhibitors have also highlighted the interest of medicinal chemists in this type of therapeutic drugs. However, adverse side effects, including bleeding complications, that have emerged in clinical studies indicate that there is still a great need for the development of more efficient and less toxic VEGFR2 inhibitors in preclinical mechanism and clinical pathology studies.

[0005] At present, the main clinical treatment for RA is drug therapy. Although these drugs can relieve the symptoms of RA to a certain extent, most of them will cause serious side effects after long-term use. With the continuous deepening of basic and clinical research, multiple RA-related genes and their protein regulatory networks have been found to play a very important role in the occurrence, development and deterioration of RA. These studies have greatly expanded the targets for new drug development, and a series of drugs for the treatment of RA have emerged. Although there are many drug treatment options available clinically, 50%-70% of RA patients still find it difficult to achieve disease remission or reduce disease activity during treatment, which ultimately leads to treatment failure. Therefore, how to safely and effectively treat RA remains an important issue facing clinical practice. Summary of the invention

[0006] The technical problem to be solved by the present invention is that there is a lack of drugs on the market that use VEGFR2 as a drug target to inhibit angiogenesis and thus prevent and treat rheumatoid arthritis, and provides aryl indazole ring compounds with better in vivo stability, preparation methods, pharmaceutical compositions and uses thereof.

[0007] The invention solves the above technical problems through the following technical solutions. The invention provides an aryl indazole ring compound, which includes a compound of formula (I) or a pharmaceutically acceptable salt thereof,

[0008]

[0009] Among them, Ar 1 Selected from the following aromatic rings or aromatic ring systems:

[0010]

[0011] Ar 2Selected from the following aromatic rings or aromatic ring systems:

[0012]

[0013] Ar 3 Selected from the following aromatic rings or aromatic ring systems:

[0014]

[0015] Wherein, the indazole ring compound as described above is selected from any one of the following compounds:

[0016]

[0017]

[0018] In one embodiment, a method for preparing the above-mentioned aryl indazole ring compound comprises the following steps:

[0019] Reactant B1 is added to a dichloromethane solution of reactant A1, and the resulting mixture is stirred at room temperature for 8 hours, then diluted with ethyl acetate and washed with water, then washed with brine, the organic layer is dried over anhydrous sodium sulfate and concentrated, the residue is diluted with dichloromethane and trifluoroacetic acid, the reaction mixture is stirred at room temperature for 4 hours, and then the pH value is adjusted to 12 with saturated sodium bicarbonate; the mixture is extracted with ethyl acetate, washed with water, then washed with brine, the organic layer is dried over sodium sulfate, filtered, concentrated, and eluted with 0-5% by volume methanol in dichloromethane through a silica gel column, chromatographed, and purified to obtain an aryl indazole ring compound.

[0020] In one embodiment, a method for preparing the above-mentioned aryl indazole ring compound comprises the following steps:

[0021] (1) adding catalyst D1 to a mixture of reactant A2 and reactant B2 in solvent C1, stirring the mixture at 80° C. for 14 h under an argon atmosphere, evaporating the solvent and diluting with ethyl acetate, then washing with water and brine, evaporating the organic phase, and eluting with 10% to 30% by volume ethyl acetate in petroleum ether by silica gel column chromatography, chromatography, and purification to obtain intermediate E1;

[0022] (2) Add reactant F1 to a dichloromethane solution of intermediate E1; stir the resulting mixture at room temperature for 8 hours, then dilute with ethyl acetate and wash with water, then wash with brine; dry the organic layer over anhydrous sodium sulfate and concentrate, dilute the residue with dichloromethane and trifluoroacetic acid, stir the reaction mixture at room temperature for 4 hours, then adjust the pH to 12 with saturated sodium bicarbonate, extract the mixture with ethyl acetate, wash with water, then wash with brine; dry the organic layer over sodium sulfate, then filter, concentrate, elute with 0-5% by volume methanol in dichloromethane, chromatograph, and purify to obtain an aryl indazole ring compound.

[0023] In one embodiment, a method for preparing the above-mentioned aryl indazole ring compound comprises the following steps:

[0024] (1) Adding catalyst D2 to a mixture of reactant A3 and reactant B3 in a dry solvent C2, stirring the mixture at 80° C. under an argon atmosphere for 14 h, evaporating the solvent and diluting with ethyl acetate, then washing with water and brine, evaporating the organic phase, eluting with a silica gel column using 10% to 30% by volume ethyl acetate in petroleum ether, chromatography, and purification to obtain intermediate E2;

[0025] (2) Add reactant F2 to a dichloromethane solution of intermediate E2, stir the resulting mixture at room temperature for 8 hours, then dilute with ethyl acetate and wash with water, then with brine, dry the organic layer over anhydrous sodium sulfate and concentrate, and dilute the residue with dichloromethane and trifluoroacetic acid; stir the reaction mixture at room temperature for 4 hours, then adjust the pH to 12 with saturated sodium bicarbonate, extract the mixture with ethyl acetate, wash with water, then with brine, dry the organic layer with sodium sulfate, then filter, concentrate, and elute with 0-5% by volume methanol in dichloromethane through a silica gel column, chromatograph, and purify to obtain intermediate E3;

[0026] (3) Adding sodium hydroxide to an anhydrous N,N-dimethylformamide solution of the intermediate E3, stirring the mixture at 0°C, adding an anhydrous N,N-dimethylformamide solution of iodine dropwise, stirring at room temperature for 4 hours, and detecting the reaction end point by LC-MS; after the reaction, the solvent was dried by spin drying, extracted with ethyl acetate, and then washed with water and saturated brine respectively, the organic layer was dried by spin drying, mixed, eluted with 0-30% by volume ethyl acetate in petroleum ether on a silica gel column, chromatographed, and purified to obtain the intermediate E4;

[0027] (4) Catalyst D3 is added to a dry N,N-dimethylformamide mixture of intermediate E4 and reactant F3, and the mixture is stirred at 80° C. under an argon atmosphere for 14 h. The solvent is evaporated and diluted with ethyl acetate, and then washed with water and brine. The organic phase is evaporated, eluted with 10% to 30% by volume ethyl acetate in petroleum ether, chromatographed, and purified to obtain an aryl indazole ring compound.

[0028] A pharmaceutical composition comprising one or more therapeutically effective amounts of the aryl indazole ring compounds represented by the general formula (I) above or pharmaceutically acceptable salts thereof, and pharmaceutically acceptable excipients.

[0029] Use of one or more aryl indazole ring compounds represented by the general formula (I) as described above or pharmaceutically acceptable salts thereof in drugs for diseases caused by up-regulation of angiogenesis by VEGFR2 kinase activity.

[0030] Further, the use of the invention in a drug for a disease caused by up-regulation of angiogenesis by VEGFR2 kinase activity, wherein the disease comprises at least one of anti-tumor therapy or rheumatic diseases such as rheumatoid arthritis, autoimmune diseases, and / or

[0031] The disease includes various inflammatory diseases, such as at least one of arthritis, asthma, and inflammatory bowel disease.

[0032] One or more aryl indazole ring compounds represented by the general formula (I) as described above or their pharmaceutically acceptable salts are used in drugs for preventing or treating rheumatoid arthritis by targeting the VEGFR2 / PI3K / AKT pathway to inhibit synovial angiogenesis.

[0033] Furthermore, the targeting of VEGFR2 / PI3K / AKT pathway to inhibit synovial angiogenesis is used in drugs for preventing or treating rheumatoid arthritis, wherein the rheumatoid arthritis disease includes at least one of joint involvement, rheumatoid vasculitis, cardiac system involvement, respiratory system involvement, kidney involvement, and blood system problems (such as anemia), pleurisy, pleural effusion, pulmonary arteritis, interstitial lung disease, glomerulonephritis, and tubulointerstitial nephritis.

[0034] The positive progress and intended effects of the present invention are:

[0035] The invention provides and proves that the aryl indazole ring compound or its pharmaceutically acceptable salt binds to the t-cell specific adaptor by phosphorylating Tyr951 of the tyrosine kinase domain of VEGFR2 under hypoxia in an in vitro experiment, triggering the activation of PI3K / AKT downstream of VEGFR2 signal transduction, thereby regulating the function of vascular endothelial cells. The above pharmacological experiments show that the aryl indazole ring compound or its pharmaceutically acceptable salt is used in the preparation of a drug for preventing or treating rheumatoid arthritis, which has a good preventive or therapeutic effect and a certain drugability.

[0036] The chemical structure of the aryl indazole ring compounds disclosed in the present invention is different from that of existing VEGFR2 inhibitors, and they are a class of VEGFR2 inhibitors with a completely new structure. In addition, the representative compounds disclosed in the present invention have good metabolic stability. DETAILED DESCRIPTION

[0037] the term

[0038] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the claimed subject matter belongs.

[0039] Unless otherwise indicated, the present invention adopts conventional methods such as mass spectrometry, NMR, HPLC, protein chemistry, biochemistry, recombinant DNA technology and pharmacology within the technical scope of the art. Unless specific definitions are provided, the nomenclature and laboratory operations and techniques related to chemical processes such as analytical chemistry, synthetic organic chemistry, and medical and pharmaceutical chemistry described herein are known to those skilled in the art. In general, the aforementioned techniques and steps can be implemented by conventional methods well known in the art and described in various general and more specific literatures, which are cited and discussed in this specification.

[0040] The term "alkyl" refers to an aliphatic hydrocarbon group, which can be a branched or straight chain alkyl. According to the structure, the alkyl can be a monovalent group or a divalent group (i.e., an alkylidene group). In the present invention, the alkyl is preferably an alkyl having 1 to 8 carbon atoms, more preferably a "low alkyl" having 1 to 6 carbon atoms, and even more preferably an alkyl having 1 to 4 carbon atoms. Typical alkyls include, but are not limited to, methyl, ethyl, propyl, butyl, pentyl, hexyl, etc. It should be understood that the "alkyl" mentioned herein includes the alkyl of all possible configurations and conformations, such as the "propyl" mentioned herein includes n-propyl and isopropyl, "butyl" includes n-butyl, isobutyl and tert-butyl, and "pentyl" includes n-pentyl, isopropyl, neopentyl, tert-pentyl, and penta-3-yl, etc.

[0041] The term "alkoxy" refers to -O-alkyl, wherein alkyl is as defined herein. Typical alkoxy groups include, but are not limited to, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, and the like.

[0042] The term "alkoxyalkyl" means an alkyl group, as defined herein, substituted with an alkoxy group, as defined herein.

[0043] The term "cycloalkyl" refers to a monocyclic or polycyclic radical containing only carbon and hydrogen. Cycloalkyl includes a group having 3-12 ring atoms. According to the structure, cycloalkyl can be a monovalent group or a divalent group (e.g., cycloalkylidene). In the present invention, cycloalkyl is preferably a cycloalkyl having 3-8 carbon atoms, more preferably a "low cycloalkyl" having 3-6 carbon atoms. The example of cycloalkyl includes, but is not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclopentenyl, cyclohexenyl, cycloheptenyl and adamantyl.

[0044] The term "alkyl (cycloalkyl)" or "cycloalkylalkyl" refers to an alkyl group, as defined herein, substituted with a cycloalkyl group, as defined herein. Non-limiting cycloalkylalkyl groups include cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl, cyclohexylmethyl, and the like.

[0045] The term "aromatic" refers to a planar ring having a delocalized π electron system and containing 4n+2 π electrons, where n is an integer. The aromatic ring may be composed of five, six, seven, eight, nine or more than nine atoms. The aromatic group may be optionally substituted. The term "aromatic" includes carbocyclic aromatic (e.g., phenyl) and heterocyclic aromatic (or "heteroaryl" or "heteroaromatic") groups (e.g., pyridine). The term includes monocyclic or fused-ring polycyclic (i.e., rings that share adjacent pairs of carbon atoms) groups.

[0046] The term "aryl" as used herein means that each of the atoms constituting the ring in the aromatic ring is a carbon atom. The aryl ring can be composed of five, six, seven, eight, nine or more than nine atoms. The aryl group can be optionally substituted. Examples of aryl groups include, but are not limited to, phenyl, naphthyl, phenanthrenyl, anthracenyl, fluorenyl and indenyl. Depending on the structure, the aryl group can be a monovalent group or a divalent group (i.e., an arylene group).

[0047] The term "aryloxy" refers to an -O-aryl group wherein aryl is as defined herein.

[0048] The term "heteroaryl" refers to an aromatic group that includes one or more ring heteroatoms selected from nitrogen, oxygen and sulfur. The N-containing "heteroaryl" part refers to an aromatic group in which at least one skeletal atom on the ring is a nitrogen atom. Depending on the structure, a heteroaryl group can be a monovalent group or a divalent group (i.e., a sub-heteroaryl group). Examples of heteroaryl groups include, but are not limited to, pyridyl, imidazolyl, pyrimidinyl, pyrazolyl, triazolyl, pyrazinyl, tetrazolyl, furyl, thienyl, isoxazolyl, thiazolyl, oxazolyl, isothiazolyl, pyrrolyl, quinolyl, isoquinolyl, indolyl, benzimidazolyl, benzofuranyl, indazolyl, indolizinyl, phthalazinyl, pyridazinyl, isoindolyl, pteridinyl, purinyl, oxadiazolyl, thiadiazolyl, furazanyl, benzofurazanyl, benzothienyl, benzothiazolyl, benzoxazolyl, quinazolinyl, naphthyridinyl and furopyridinyl, etc.

[0049] The term "alkyl (aryl)" or "aralkyl" refers to an alkyl group, as defined herein, substituted with an aryl group, as defined herein. Non-limiting examples of alkyl (aryl) groups include benzyl, phenethyl, and the like.

[0050] The term "alkyl(heteroaryl)" or "heteroarylalkyl" means an alkyl group, as defined herein, substituted with a heteroaryl group, as defined herein.

[0051] The term "heteroalkyl" as used herein refers to an alkyl group as defined herein where one or more of the backbone chain atoms is a heteroatom, such as oxygen, nitrogen, sulfur, silicon, phosphorus, or a combination thereof. The heteroatom(s) may be located at any position within the heteroalkyl group or at a position where the heteroalkyl group is attached to the rest of the molecule.

[0052] The term "heterocycloalkyl" or "heterocyclic group" as used herein refers to a non-aromatic ring in which one or more atoms constituting the ring are heteroatoms selected from nitrogen, oxygen and sulfur. The heterocycloalkyl ring can be composed of three, four, five, six, seven, eight, nine or more than nine atoms. The heterocycloalkyl ring can be optionally substituted. Examples of heterocycloalkyl include, but are not limited to, lactams, lactones, cyclic imines, cyclic thioimides, cyclic carbamates, tetrahydrothiopyrans, 4H-pyrans, tetrahydropyrans, piperidines, 1,3-dioxins, 1,3-dioxanes, 1,4-dioxins, 1,4-dioxanes, piperazines, 1,3-oxathiacyclohexanes, 1,4-oxathiacyclohexanes, 1,4-oxathiacyclohexanes, tetrahydro-1,4-thiazine, 2H-1,2-oxazine, maleimide, succinimide, barbituric acid, thiobarbital Acid, dioxopiperazine, hydantoin, dihydrouracil, morpholine, trioxane, hexahydro-1,3,5-triazine, tetrahydrothiophene, tetrahydrofuran, pyrroline, pyrrolidine, imidazolidine, pyrrolidone, pyrazoline, pyrazolidine, imidazoline, imidazolidine, 1,3-dioxole, 1,3-dioxolane, 1,3-dithiole, 1,3-dithiolane, isoxazoline, isoxazolidine, oxazoline, oxazolidine, oxazolidinone, thiazoline, thiazolidine and 1,3-oxathiolane. Depending on the structure, the heterocycloalkyl group can be a monovalent group or a divalent group (i.e., a heterocycloalkylene group).

[0053] The term "alkyl(heterocycloalkyl)" or "heterocycloalkylalkyl" means an alkyl group, as defined herein, substituted with a heterocycloalkyl group, as defined herein.

[0054] The term "alkoxy(heterocycloalkyl)" or "heterocycloalkylalkoxy" means an alkoxy group, as defined herein, substituted with a heterocycloalkyl group, as defined herein.

[0055] The term "halo" or "halogen" refers to fluorine, chlorine, bromine and iodine.

[0056] The terms "haloalkyl", "haloalkoxy" and "haloheteroalkyl" include structures of alkyl, alkoxy or heteroalkyl, wherein at least one hydrogen is replaced by a halogen atom. In certain embodiments, if two or more hydrogen atoms are replaced by halogen atoms, the halogen atoms may be the same or different from each other.

[0057] The term "hydroxy" refers to an -OH group.

[0058] The term "cyano" refers to a -CN group.

[0059] The term "ester group" refers to a chemical moiety having the formula -COOR, where R is selected from alkyl, cycloalkyl, aryl, heteroaryl (attached through a ring carbon), and heterocyclyl (attached through a ring carbon).

[0060] The term "amino" refers to a -NH2 group.

[0061] The term "aminoacyl" refers to a -CO-NH2 group.

[0062] The term "amido" or "amido" refers to -NR-CO-R', wherein R and R' are each independently hydrogen or alkyl.

[0063] The term "alkylamino" refers to an amino substituent further substituted with one or two alkyl groups, specifically the group -NRR', wherein R and R' are each independently selected from hydrogen or lower alkyl, provided that -NRR' is not -NH2. "Alkylamino" includes groups of compounds in which the nitrogen of -NH2 is connected to at least one alkyl group. Examples of alkylamino groups include, but are not limited to, methylamino, ethylamino, etc. "Dialkylamino" includes groups in which the nitrogen of -NH2 is connected to at least two other alkyl groups. Examples of dialkylamino groups include, but are not limited to, dimethylamino, diethylamino, etc.

[0064] The terms "arylamino" and "diarylamino" refer to amino substituents further substituted with one or two aryl groups, specifically the group -NRR', wherein R and R' are each independently selected from hydrogen, lower alkyl, or aryl, wherein N is attached to at least one or two aryl groups, respectively.

[0065] The term "cycloalkylamino" refers to an amino substituent further substituted with one or two cycloalkyl groups as defined herein.

[0066] The term "heteroalkylamino" refers to an amino substituent further substituted with one or two heteroalkyl groups as defined herein.

[0067] The term "aralkylamino" herein refers to the group -NRR' wherein R is lower aralkyl and R' is hydrogen, lower alkyl, aryl or lower aralkyl.

[0068] The term "heteroarylamino" refers to an amino substituent further substituted with one or two heteroaryl groups as defined herein.

[0069] The term "heterocycloalkylamino" means an amino group, as defined herein, substituted with a heterocycloalkyl group, as defined herein.

[0070] The term "alkylaminoalkyl" means an alkyl group, as defined herein, substituted with an alkylamino group, as defined herein.

[0071] The term "aminoalkyl" refers to an alkyl substituent further substituted with one or more amino groups.

[0072] The term "aminoalkoxy" refers to an alkoxy substituent further substituted with one or more amino groups.

[0073] The term "hydroxyalkyl" or "hydroxyalkyl" refers to an alkyl substituent further substituted with one or more hydroxy groups.

[0074] The term "cyanoalkyl" refers to an alkyl substituent further substituted with one or more cyano groups.

[0075] The term "acyl" refers to a monovalent atomic radical remaining after removing a hydroxyl group from an organic or inorganic oxygen-containing acid, and has the general formula RM(O)-, wherein M is usually C.

[0076] The term "carbonyl" refers to an organic functional group consisting of two atoms, carbon and oxygen, connected by a double bond (C=O).

[0077] The term "alkanoyl" or "alkylcarbonyl" refers to a carbonyl group further substituted with an alkyl group. Typical alkanoyl groups include, but are not limited to, acetyl, propionyl, butyryl, valeryl, hexanoyl, and the like.

[0078] The term "arylcarbonyl" means a carbonyl group, as defined herein, substituted with an aryl group, as defined herein.

[0079] The term "alkoxycarbonyl" refers to a carbonyl group further substituted with an alkoxy group.

[0080] The term "heterocycloalkylcarbonyl" refers to a carbonyl group further substituted with a heterocycloalkyl group.

[0081] The terms "alkylaminocarbonyl", "cycloalkylaminocarbonyl", "arylaminocarbonyl", "aralkylaminocarbonyl", "heteroarylaminocarbonyl" respectively refer to a carbonyl group, as defined herein, substituted with an alkylamino, cycloalkylamino, arylamino, aralkylamino, or heteroarylamino group, as defined herein respectively.

[0082] The term "alkylcarbonylalkyl" or "alkanoylalkyl" refers to an alkyl group further substituted with an alkylcarbonyl group.

[0083] The term "alkylcarbonylalkoxy" or "alkanoylalkoxy" refers to an alkoxy group further substituted with an alkylcarbonyl group.

[0084] The term "heterocycloalkylcarbonylalkyl" refers to an alkyl group further substituted with a heterocycloalkylcarbonyl group.

[0085] The term "mercapto" refers to a -SH group. The term "alkylthio" refers to a mercapto group, as defined herein, substituted with an alkyl group, as defined herein.

[0086] The term "optionally" refers to one or more events described later that may or may not occur, and includes both events that occur and events that do not occur. The term "optionally substituted" or "substituted" refers to that the group mentioned may be substituted by one or more additional groups, and the additional groups are each and independently selected from alkyl, cycloalkyl, aryl, heteroaryl, heterocyclic radical, hydroxyl, alkoxy, cyano, halogen, amide, nitro, haloalkyl, amino, methylsulfonyl, alkylcarbonyl, alkoxycarbonyl, heteroarylalkyl, heterocycloalkylalkyl, aminoacyl, amino protecting group, etc. Wherein, amino protecting group is preferably selected from pivaloyl, tert-butyloxycarbonyl, benzyloxycarbonyl, 9-fluorenylmethyloxycarbonyl, benzyl, p-methoxybenzyl, allyloxycarbonyl, and trifluoroacetyl, etc.

[0087] As used herein, the terms "inhibition," "inhibited," or "inhibitor" of a kinase refer to inhibition of phosphotransferase activity.

[0088] The "metabolites" of the compounds disclosed herein are derivatives of the compounds formed when the compounds are metabolized. The term "active metabolite" refers to the biologically active derivatives of the compounds formed when the compounds are metabolized. The term "metabolized" as used herein refers to the sum of processes in which a specific substance is changed by an organism (including but not limited to hydrolysis reactions and reactions catalyzed by enzymes, such as oxidation reactions). Therefore, enzymes can produce specific structural changes to compounds. For example, cytochrome P450 catalyzes various oxidation and reduction reactions, while diphosphotransferase catalyzes the conversion of activated glucuronic acid molecules to aromatic alcohols, aliphatic alcohols, carboxylic acids, amines and free sulfhydryl groups. Further information on metabolism can be obtained from "The Pharmacological Basis of Therapeutics", Ninth Edition, McGraw-Hill (1996). The metabolites of the compounds disclosed herein can be identified by administering the compounds to a host and analyzing tissue samples from the host, or by incubating the compounds with hepatocytes in vitro and analyzing the resulting compounds. Both methods are known in the art. In some embodiments, the metabolites of the compounds are formed by oxidation processes and correspond to the corresponding hydroxyl-containing compounds. In some embodiments, the compound is metabolized to a pharmaceutically active metabolite. The term "modulate" as used herein refers to interacting directly or indirectly with a target to change the activity of the target, including, by way of example only, enhancing the activity of the target, inhibiting the activity of the target, limiting the activity of the target, or prolonging the activity of the target.

[0089] The term "target protein" as used herein refers to a protein molecule or a portion of a protein that can be bound by a selective binding compound. In certain embodiments, the target protein is a tyrosine kinase KIT (wild type or various mutations or combinations thereof), ABL (wild type or various mutations or combinations thereof), EGFR (wild type or various mutations or combinations thereof), FLT3 (wild type or various mutations or combinations thereof), VEGFR2 (wild type or various mutations or combinations thereof), RET (wild type or various mutations or combinations thereof), PDGFRα (wild type or various mutations or combinations thereof), PDGFRβ (wild type or various mutations or combinations thereof), BCR / ABL (wild type or various mutations or combinations thereof), FGFR1 (wild type or various mutations or combinations thereof), FGFR2 (wild type or various mutations or combinations thereof), FGFR3 (wild type or various mutations or combinations thereof), FGFR4 (wild type or various mutations or combinations thereof).

[0090] IC used in this article 50 It refers to the amount, concentration or dose of a particular test compound that achieves a 50% inhibition of the maximal effect in an assay measuring such effect.

[0091] The EC used in this paper 50 It refers to the dose, concentration or amount of a test compound which elicits a dose-dependent response of 50% of the maximal expression of a specific response induced, stimulated or potentiated by the particular test compound.

[0092] The GI used in this paper 50 It refers to the drug concentration required to inhibit 50% of cell growth, that is, the drug concentration at which the growth of 50% of cells (such as cancer cells) is inhibited or controlled.

[0093] The following is a detailed description of an embodiment of the present invention. This embodiment is implemented on the premise of the technical solution of the present invention, and a detailed implementation method and a specific operation process are given, but the protection scope of the present invention is not limited to the following embodiment.

[0094] Compounds, pharmaceutical compositions and uses

[0095] An aryl indazole ring compound, comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof,

[0096]

[0097] Among them, Ar 1 Selected from the following aromatic rings or aromatic ring systems:

[0098]

[0099] Ar 2 Selected from the following aromatic rings or aromatic ring systems:

[0100]

[0101] Ar 3 Selected from the following aromatic rings or aromatic ring systems:

[0102]

[0103] A pharmaceutical composition comprising one or more therapeutically effective amounts of the aryl indazole ring compounds represented by the general formula (I) above or pharmaceutically acceptable salts thereof, and pharmaceutically acceptable excipients.

[0104] Use of one or more aryl indazole ring compounds represented by the general formula (I) as described above or pharmaceutically acceptable salts thereof in drugs for diseases caused by up-regulation of angiogenesis by VEGFR2 kinase activity.

[0105] Further, the use of the invention in a drug for a disease caused by up-regulation of angiogenesis by VEGFR2 kinase activity, wherein the disease comprises at least one of anti-tumor therapy or rheumatic diseases such as rheumatoid arthritis, autoimmune diseases, and / or

[0106] The disease includes various inflammatory diseases, such as at least one of arthritis, asthma, and inflammatory bowel disease.

[0107] One or more aryl indazole ring compounds represented by the general formula (I) as described above or their pharmaceutically acceptable salts are used in drugs for preventing or treating rheumatoid arthritis by targeting the VEGFR2 / PI3K / AKT pathway to inhibit synovial angiogenesis.

[0108] Furthermore, the targeting of VEGFR2 / PI3K / AKT pathway to inhibit synovial angiogenesis is used in drugs for preventing or treating rheumatoid arthritis, wherein the rheumatoid arthritis disease includes at least one of joint involvement, rheumatoid vasculitis, cardiac system involvement, respiratory system involvement, kidney involvement, and blood system problems (such as anemia), pleurisy, pleural effusion, pulmonary arteritis, interstitial lung disease, glomerulonephritis, and tubulointerstitial nephritis.

[0109] Preparation of compounds

[0110] Compounds of formula (I) may be synthesized using standard synthesis techniques known to those skilled in the art or using methods known in the art in combination with the methods described herein. In addition, the solvents, temperatures and other reaction conditions given herein may be varied according to the art. As further guidance, the following synthesis methods may also be utilized.

[0111] The reactions can be used sequentially to provide compounds described herein; or they can be used to synthesize fragments that are subsequently added by methods described herein and / or known in the art.

[0112] In certain embodiments, provided herein are methods for preparing kinase inhibitor compounds described herein and methods of using them. In certain embodiments, the compounds described herein can be synthesized using the following synthetic schemes. Compounds can be synthesized using methods similar to those described below by using appropriate optional starting materials.

[0113] The starting materials for synthesizing the compounds described herein can be synthesized or can be obtained from commercial sources. The compounds described herein and other related compounds with different substituents can be synthesized using techniques and raw materials known to those skilled in the art. The general method for preparing the compounds disclosed herein can be from reactions known in the art, and the reactions can be modified by reagents and conditions deemed appropriate by those skilled in the art to introduce various parts into the molecules provided herein.

[0114] If desired, the reaction products can be isolated and purified using conventional techniques, including but not limited to filtration, distillation, crystallization, chromatography, etc. These products can be characterized using conventional methods, including physical constants and spectral data.

[0115] Example 1

[0116] The synthetic reaction formula is as follows:

[0117]

[0118] The synthesis steps are as follows:

[0119] (1) To a mixture of 2 g (4.63 mmol) of (E)-6-iodo-3-(2-(pyridin-2-yl)vinyl)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole and 0.7 g (5.11 mmol) of 2-aminophenylboronic acid in anhydrous N,N-dimethylformamide, 0.27 g (0.23 mmol) of tetrakis(triphenylphosphine)palladium and 1.28 g (9.28 mmol) of potassium carbonate were added, and the mixture was stirred at 80° C. for 14 h under an argon atmosphere; the solvent was evaporated and diluted with ethyl acetate, then washed with water and brine, the organic phase was evaporated, and eluted with 10% to 30% ethyl acetate in petroleum ether by silica gel column chromatography, chromatographed, and purified to obtain 1.4 g of the intermediate (E)-2-(3-(2-(pyridin-2-yl)vinyl)-1H-indazole-6-yl)aniline as a white solid, with a yield of 76%);

[0120] (2) (E)-2-(3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)aniline was added to 5 mL of dichloromethane to form a solution, and 56 mg (0.36 mmol) of 3-fluorobenzoic acid, 165 mg (0.43 mmol) of 2-(7-azobenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate and 86 mg (0.67 mmol) of N,N-diisopropylethylamine were added thereto. The resulting mixture was stirred at room temperature for 8 h; then diluted with 50 mL of ethyl acetate and washed three times with 100 mL of water and then with 100 mL of brine. The organic layer was stirred in anhydrous sulfuric acid. The mixture was dried over sodium and concentrated. The residue was diluted with 5 mL of dichloromethane and 1 mL of trifluoroacetic acid. The reaction mixture was stirred at room temperature for 4 h, and then the pH value was adjusted to 12 with saturated sodium bicarbonate. The mixture was extracted with 50 mL of ethyl acetate, washed twice with 50 mL of water, and then washed with 50 mL of brine. The organic layer was dried over sodium sulfate, filtered, concentrated, and eluted with 0-5% methanol in dichloromethane on a silica gel column, chromatographed, and purified to obtain 60 mg of (E)-3-fluoro-N-(2-(3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)phenyl)benzamide as a yellow solid in a yield of 55%.

[0121] The product H NMR spectrum is: 1 H NMR (500MHz, DMSO-d6) δ13.32(s,1H),10.04(s,1H),8.62–8.58(m,1H),8.19(d,J=8. 4Hz,1H),7.96(d,J=16.4Hz,1H),7.80(td,J=7.7,1.8Hz,1H),7.68–7.63(m,2H),7.59 (s,2H),7.57(d,J=7.0Hz,1H),7.55–7.52(m,2H),7.51–7.47(m,2H),7.47–7.43(m,1 H),7.40–7.35(m,1H),7.31(dd,J=8.4,1.1Hz,1H),7.26(ddd,J=7.4,4.8,0.9Hz,1H). 13C NMR(126MHz,DMSO-d6)δ165.02,163.31,161.37,155.48,149.99,142.19,138.79,137.90,137.31,137.28,137.26,135.28,131.10 ,131.05,130.99,129.31,128.83,128.47,127.45,124.55,124.12,123.03,122.84,120.75,118.89,114.85,110.71.HRMS(ESI)m / z calcd for C 27 H 19 FN4O[M+H]+435.1616; found,435.1619.

[0122] Example 2

[0123] To synthesize (E)-3-fluoro-N-(3-(3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)phenyl)benzamide, (E)-6-iodo-3-(2-(pyridin-2-yl)vinyl)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole and 3-aminophenylboronic acid were selected as raw materials, and the other embodiments were the same as those in Example 1;

[0124] The prepared compound was a light yellow solid with a yield of 76.0%;

[0125] The product H NMR spectrum is: 1 H NMR (500MHz, DMSO-d6) δ13.48(s,1H),10.51(s,1H),8.63(d,J=4.4Hz,1H),8.31(d,J=8.5Hz,1H),8.24(s,1H),8.00(d,J= 16.4Hz,1H),7.91–7.79(m,5H),7.71(d,J=7.8Hz,1H),7.65–7.60(m,2H),7.57–7.45(m,4H),7.29(dd,J=7.2,4.9Hz,1H). 13C NMR (126MHz, DMSO-d6) δ164.72,163.40,161.46,155.49,150.02,141.22,140.04,138.96,137.65,137.33,131.12,131.06,129.84 ,129.44,124.44,123.15,123.03,122.89,121.73,121.26,120.70,120.00,119.62,119.12,118.95,115.12,114.94.HRMS(ESI)m / z calcd for C 27 H 19 FN4O[M+H]+435.1616; found,435.1617.

[0126] Example 3

[0127] To synthesize (E)-3-fluoro-N-(4-(3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)phenyl)benzamide, (E)-6-iodo-3-(2-(pyridin-2-yl)vinyl)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole and 4-aminophenylboronic acid were selected as raw materials, and the other embodiments were the same as those in Example 1;

[0128] The prepared compound was a light yellow solid with a yield of 79.3%;

[0129] The product H NMR spectrum is: 1 H NMR (500MHz, DMSO-d6) δ13.51(s,1H),10.61(s,1H),8.62(d,J=4.1Hz,1H),8.27(d,J=8.5Hz,1H),8.02–7.97(m,3H),7.90(dd,J=16.5,8. 7Hz,2H),7.82(dt,J=19.3,5.0Hz,4H),7.71(d,J=7.8Hz,1H),7.64–7.55(m,3H),7.47(td,J=8.5,2.1Hz,1H),7.29(dd,J=6.9,5.1Hz,1H). 13C NMR (126MHz, DMSO-d6) δ164.65,163.38,161.44,155.52,150.02,142.65,142.17,139.09,138.60,137.62,137.33,136.10 ,131.07,129.32,127.77,124.52,123.03,122.86,121.60,121.35,121.13,120.41,115.19,115.01,108.12.HRMS(ESI)m / z calcd for C 27 H 19 FN4O[M+H] + 435.1616; found, 435.1610.

[0130] Example 4

[0131] The synthetic reaction formula is as follows:

[0132]

[0133] The synthesis steps are as follows:

[0134] (1) To a mixture of 0.63 g (5.09 mmol) of (E)-6-iodo-3-(2-(pyridin-2-yl)vinyl)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole and 0.63 g (5.09 mmol) of 2-aminothiophenol in dry 1,4-dioxane were added 0.2 g (0.23 mmol) of tris(dibenzylideneacetone)dipalladium, 0.5 g (0.87 mmol) of 4,5-bis(diphenylphosphine)-9,9-dimethylxanthene and 1.28 g (9. 28mmol) potassium carbonate, the mixture was stirred at 80°C under an argon atmosphere for 14h, the solvent was evaporated and diluted with ethyl acetate, and then washed with water and brine; the organic phase was evaporated, eluted with 10%-30% ethyl acetate in petroleum ether on a silica gel column, chromatographed and purified to obtain 1.2g of the intermediate (E)-3-((3-(2-(pyridin-2-yl)vinyl)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-6-yl)thio)aniline as a yellow solid, with a yield of 65.2%;

[0135] (2) To 5 mL of dichloromethane was added (E)-3-((3-(2-(pyridin-2-yl)vinyl)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-6-yl)thio)aniline to form a solution, and then 56 mg (0.36 mmol) of 3-fluorobenzoic acid, 165 mg (0.43 mmol) of 2-(7-azobenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate and 86 mg (0.67 mmol) of N,N-diisopropylethylamine were added. The resulting mixture was stirred at room temperature for 8 h, then diluted with 50 mL of ethyl acetate and washed three times with 100 mL of water, and then washed with 100 mL of brine; The organic layer was dried over anhydrous sodium sulfate and concentrated, and the residue was diluted with 5 mL of dichloromethane and 1 mL of trifluoroacetic acid. The reaction mixture was stirred at room temperature for 4 h, and then the pH value was adjusted to 12 with saturated sodium bicarbonate, and the mixture was extracted with 50 mL of ethyl acetate, washed twice with 50 mL of water, and then washed with 50 mL of brine; the organic layer was dried over sodium sulfate, filtered, concentrated, and eluted with 0-5% volume fraction of methanol in dichloromethane on a silica gel column, chromatographed, and purified to obtain 68 mg of (E)-3-fluoro-N-(2-(3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)phenyl)benzamide as a yellow solid in a yield of 60.4%;

[0136] The product H NMR spectrum is: 1 H NMR (500MHz, DMSO-d6) δ13.24(s,1H),10.18(s,1H),8.60(d,J=4.2Hz,1H),8.14(d,J=8.5Hz,1H),7.92(d,J=16.4Hz,1H),7.80(td,J=7.6,1.4Hz ,1H),7.74(d,J=7.7Hz,1H),7.65(d,J=8.1Hz,3H),7.57–7.52(m,2H),7 .47–7.40(m,3H),7.37(s,1H),7.32–7.25(m,2H),7.11(d,J=8.6Hz,1H). 13 C NMR (126MHz, DMSO-d6) δ164.66,163.38,161.43,155.34,150.01,142.41,142.27,138.17,137.33,136.89,134.02,133.57,131.27 ,131.18,129.64,129.10,127.66,127.62,124.13,123.74,123.11,122.94,122.08,120.25,119.24,114.88,111.97.HRMS(ESI)m / z calcd for C27 H 19 FN4OS[M+H]+467.1336; found,467.1310;

[0137] Example 5

[0138] To synthesize (E)-3-fluoro-N-(4-(3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)phenyl)benzamide, (E)-6-iodo-3-(2-(pyridin-2-yl)vinyl)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole and 3-aminothiophenol were selected as raw materials, and the other embodiments were the same as those in Example 4;

[0139] The prepared compound was a light yellow solid with a yield of 75.5%;

[0140] The product H NMR spectrum is: 1 H NMR(500MHz,DMSO-d6)δ13.29(s,1H),10.40(s,1H),8.61(d,J=4.7Hz,1H),8.21(d,J=8.5Hz,1H),7.98–7.87(m,2H),7.84–7.77(m,3H),7 .77–7.70(m,1H),7.67(d,J=7.8Hz,1H),7.61–7.54(m,2H),7.50–7.40(m,3H),7.28(dd,J=7.5,4.8Hz,1H),7.19(dd,J=12.2,8.1Hz,2H). 13 C NMR (126MHz, DMSO-d6) δ164.81,163.35,161.40,155.36,150.04,142.49,142.35,140.54,137.34,135.39,133.85,131.05,130.38 ,129.72,126.93,124.41,124.39,124.13,123.12,122.99,122.20,120.40,120.05,119.01,115.10,114.92,112.41.HRMS(ESI)m / z calcd for C 27 H 19 FN4OS[M+H]+467.1336; found,467.1343.

[0141] Example 6

[0142] To synthesize (E)-4-fluoro-N-(4-(3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)phenyl)benzamide, (E)-6-iodo-3-(2-(pyridin-2-yl)vinyl)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole and 4-aminothiophenol were selected as raw materials, and the other embodiments were the same as those in Example 4;

[0143] The prepared compound was a light yellow solid with a yield of 68.5%;

[0144] The product H NMR spectrum is: 1 H NMR (500MHz, DMSO-d6) δ13.19(s,1H),10.50(s,1H),8.61(d,J=4.1Hz,1H),8.17(d,J=8.5Hz,1H),7.93–7.88(m,3H),7.84–7.78(m,3H),7.6 6(d,J=7.8Hz,1H),7.61(td,J=8.0,6.1Hz,1H),7.55–7.51(m,3H),7.47(td,J=8.4,2.1Hz,1H),7.28(d,J=4.3Hz,2H),7.13(d,J=8.5Hz,1H). 13 C NMR (126MHz, DMSO-d6) δ164.84,163.37,161.43,155.36,150.01,142.42,139.77,137.32,136.06,134.07,131.15,131.08 ,129.62,127.85,124.45,124.19,123.08,122.93,122.66,121.94,119.90,119.20,119.03,115.13,110.18.HRMS(ESI)m / z calcd for C 27 H 19 FN4OS[M+H]+467.1336; found,467.1335.

[0145] Example 7

[0146] The synthetic reaction formula is as follows:

[0147]

[0148] The synthesis steps are as follows:

[0149] (1) To a mixture of 2 g (4.63 mmol) of (E)-6-iodo-3-(2-(pyridin-2-yl)vinyl)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole and 0.63 g (3.89 mmol) of 3-mercaptobenzoic acid in dry 1,4-dioxane were added 0.2 g (0.23 mmol) of tris(dibenzylideneacetone)dipalladium, 0.5 g (0.87 mmol) of 4,5-bis(diphenylphosphine)-9,9-dimethylxanthene and 1.28 g (9.2 8mmol) potassium carbonate, the mixture was stirred at 80°C under an argon atmosphere for 14h; the solvent was evaporated and diluted with ethyl acetate, then washed with water and brine, the organic phase was evaporated, eluted with 10%-30% ethyl acetate in petroleum ether on a silica gel column, chromatographed, and purified to obtain 1.2g of the intermediate (E)-3-((3-(2-(pyridin-2-yl)vinyl)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-6-yl)thio)aniline as a yellow solid, with a yield of 65.2%;

[0150] (2) To 5 mL of dichloromethane was added 100 mg (0.22 mmol) of (E)-3-((3-(2-(pyridin-2-yl)vinyl)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-6-yl)thio)aniline to form a solution, and then 24 mg (0.22 mmol) of 3-fluoroaniline, 165 mg (0.43 mmol) of 2-(7-azobenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate and 86 mg (0.67 mmol) of N,N-diisopropylethylamine were added, and the resulting mixture was stirred at room temperature for 8 h; then diluted with 50 mL of ethyl acetate and washed three times with 100 mL of water, and then washed with 10 The mixture was extracted with 50 mL of ethyl acetate, washed twice with 50 mL of water, then washed with 50 mL of brine, the organic layer was dried over anhydrous sodium sulfate and concentrated, the residue was diluted with 5 mL of dichloromethane and 1 mL of trifluoroacetic acid, the reaction mixture was stirred at room temperature for 4 h, and the pH value was adjusted to 12 with saturated sodium bicarbonate; the mixture was extracted with 50 mL of ethyl acetate, washed twice with 50 mL of water, and then washed with 50 mL of brine, the organic layer was dried over sodium sulfate, and then eluted with 0-5% volume fraction of methanol in dichloromethane, chromatographed, and purified by silica gel column to obtain 60 mg of (E)-N-(3-fluorophenyl)-3-((3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thio)benzamide as a yellow solid, with a yield of 59.2%;

[0151] The product H NMR spectrum is: 1H NMR (500MHz, DMSO-d6) δ13.25(s,1H),10.44(s,1H),8.54(d,J=4.3Hz,1H),8.16(d,J=8. 5Hz,1H),7.94–7.83(m,3H),7.74(td,J=7.7,1.5Hz,1H),7.66(d,J=11.7Hz,1H),7.59(d, J=7.8Hz,1H),7.51(d,J=5.4Hz,2H),7.46(dd,J=15.4,10.0Hz,3H),7.31(dd,J=15.2,8. 0Hz, 1H), 7.21 (dd, J=7.0, 5.1Hz, 1H), 7.15 (d, J=8.6Hz, 1H), 6.87 (td, J=8.4, 2.1Hz, 1H). 13 C NMR(126MHz,DMSO-d6)δ165.35,163.45,161.53,155.32,150.03,142.51,141.21,137.35,136.29,136.03,134.41,133.05,130.76 ,130.32,130.19,129.79,127.38,124.39,124.03,123.13,122.98,122.39,120.57,116.56,113.05,110.86,107.66.HRMS(ESI)m / z calcd for C 27 H 19 FN4OS[M+H]+467.1336; found,467.1368.

[0152] Example 8

[0153] To synthesize (E)-2-(3-fluorophenyl)-N-(3-((3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thio)phenyl)acetamide, (E)-3-((3-(2-(pyridin-2-yl)vinyl)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-6-yl)thio)aniline and m-fluorophenylacetic acid were selected as raw materials, and other embodiments were the same as those in Example 4;

[0154] The prepared compound was a light yellow solid with a yield of 66.5%;

[0155] The product H NMR spectrum is: 1H NMR (500MHz, DMSO-d6) δ13.28 (s, 1H), 10.29 (s, 1H), 8.61 (d, J = 4.1Hz, 1H), 8.20 (d,J=8.5Hz,1H),7.94(d,J=16.4Hz,1H),7.81(td,J=7.7,1.6Hz,1H),7.67(d,J =6.7Hz,2H),7.58(t,J=14.2Hz,2H),7.46(s,1H),7.38–7.33(m,2H),7.28(dd,J =7.0,5.1Hz,1H),7.16(dd,J=15.3,8.8Hz,3H),7.11–7.05(m,2H),3.66(s,2H). 13 CNMR(126MHz,DMSO-d6)δ169.26,163.46,155.33,150.02,142.46,140.68,138.90,137.34,135.62,133.62,130.63,130.46,130.12,12 9.71,126.14,125.82,124.25,124.09,123.12,122.97,122.21,121.50,120.39,118.71,116.55,113.95,112.59,43.19.HRMS(ESI)m / z calcd for C 26 H 23 N3O3S[M+H]+458.1533; found,458.1598.

[0156] Example 9

[0157] The synthetic reaction formula is as follows:

[0158]

[0159] The synthesis steps are as follows:

[0160] 50 mg (0.12 mmol) of (E)-3-((3-(2-(pyridin-2-yl)vinyl)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-6-yl)thio)aniline was added to 20 mL of dichloromethane to form a solution, and 16 mg (0.12 mmol) of 3-fluorophenyl isocyanate was added. The resulting mixture was stirred at room temperature for 8 h and then concentrated to dryness; the residue was diluted with 2 mL of dichloromethane and 1 mL of trifluoroacetic acid, the reaction mixture was stirred at room temperature for 4 h, and then washed with saturated sodium bicarbonate. and sodium bicarbonate to adjust the pH to 12, extract the mixture with 50 mL of ethyl acetate, wash twice with 50 mL of water, and then wash with 50 mL of brine, dry the organic layer over sodium sulfate, filter, concentrate, and elute with 0-5% by volume methanol in dichloromethane, chromatograph, and purify through a silica gel column to obtain 30 mg of (E)-1-(3-fluorophenyl)-3-(3-((3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thio)phenyl)urea as a white solid in a yield of 54.8%;

[0161] The product H NMR spectrum is: 1 H NMR (500MHz, DMSO-d6) δ13.29(s,1H),9.34–9.25(m,2H),8.61(d,J=4.2Hz,1H),8.20(d,J= 8.5Hz,1H),7.94(d,J=16.4Hz,1H),7.81(td,J=7.7,1.4Hz,1H),7.66(d,J=7.8Hz,1H),7.59 –7.54(m,2H),7.48–7.42(m,3H),7.34(t,J=7.9Hz,1H),7.28(dd,J=14.4,7.7Hz,2H),7.18 (d,J=8.6Hz,1H),7.10(d,J=9.0Hz,1H),7.02(d,J=7.7Hz,1H),6.77(td,J=8.5,2.3Hz,1H). 13 C NMR (126MHz, DMSO-d6) δ163.80,161.88,155.35,152.85,150.02,142.45,142.01,141.22,137.33,135.30,134.00,130.80,130.51 ,130.11,129.68,125.04,124.14,123.12,122.95,122.15,120.77,120.30,117.95,114.35,112.18,108.71,105.15.HRMS(ESI)m / z calcd for C 27 H 20FN5OS[M+H]+482.1445; found,482.1440.

[0162] Example 10

[0163] Synthesis of (E)-N-(3-((3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thio)phenyl)propanamide Select (E)-3-((3-(2-(pyridin-2-yl)vinyl)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-6-yl)thio)aniline and propionic acid as raw materials, and other implementation methods are the same as Example 4;

[0164] The prepared compound was a light yellow solid with a yield of 56.5%;

[0165] The product H NMR spectrum is: 1 H NMR (500MHz, DMSO-d6) δ13.32(s,1H),10.02(s,1H),8.61(d,J=4.4Hz,1H),8.20(d,J=8 .5Hz,1H),7.93(dd,J=16.4,6.3Hz,1H),7.84–7.79(m,1H),7.70–7.65(m,2H),7.58(dt, J=16.3,7.9Hz,2H),7.45(s,1H),7.34(t,J=8.0Hz,1H),7.28(dd,J=6.9,5.2Hz,1H),7. 17(d,J=9.3Hz,1H),7.07(d,J=7.7Hz,1H),2.29(q,J=7.5Hz,2H),1.05(t,J=7.6Hz,3H). 13 C NMR(126MHz,DMSO-d6)δ172.70,155.34,150.02,140.99,137.35,135.34,133.82,130.36,129.68,125.83,125.58,1 24.14,123.12,122.97,122.18,121.49,120.33,119.17,118.72,118.63,112.42,29.95,10.00.HRMS(ESI)m / zcalcd for C 23 H 20 N4OS[M+H]+401.1431; found,401.1439.

[0166] Embodiment 11

[0167] Synthesis of (E)-N-(3-((3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thio)phenyl)butanamide Select (E)-3-((3-(2-(pyridin-2-yl)vinyl)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-6-yl)thio)aniline and n-butyric acid as raw materials, and other implementation methods are the same as Example 4;

[0168] The prepared compound was a light yellow solid with a yield of 62.8%;

[0169] The product H NMR spectrum is: 1 H NMR (500MHz, DMSO-d6) δ13.31(s,1H),10.00(s,1H),8.65(d,J=4.4Hz,1H),8.25(d,J=8.5Hz,1 H),7.98(dd,J=16.4,6.4Hz,1H),7.85(dd,J=10.8,4.5Hz,1H),7.71(d,J=8.3Hz,2H),7.67–7.5 8(m,2H),7.50(s,1H),7.39(dd,J=16.7,8.7Hz,1H),7.32(dd,J=6.8,5.3Hz,1H),7.24–7.21(m, 1H), 7.12 (d, J = 7.7Hz, 1H), 2.30 (t, J = 7.3Hz, 2H), 1.62 (h, J = 7.4Hz, 2H), 0.93 (t, J = 7.4Hz, 3H). 13 C NMR (126MHz, DMSO-d6) δ171.84,155.34,150.02,142.37,140.92,137.34,135.39,133.79,130.37,129.69,125.87,1 24.18,123.12,122.96,122.18,121.47,120.35,119.20,118.64,116.96,114.04,38.77,18.90,14.07.HRMS(ESI)m / z calcd for C 24 H 22 N4OS[M+H]+415.1587; found,415.1586.

[0170] Example 12

[0171] Synthesis of (E)-N-(3-((3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thio)phenyl)isobutyramide Select (E)-3-((3-(2-(pyridin-2-yl)vinyl)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-6-yl)thio)aniline and isobutyric acid as raw materials, and other implementation methods are the same as Example 4;

[0172] The prepared compound was a light yellow solid with a yield of 68.5%;

[0173] The product H NMR spectrum is: 1 H NMR (500MHz, DMSO-d6) δ13.28(s,1H),9.94(s,1H),8.61(d,J=4.1Hz,1H),8.20(d,J=8.5Hz,1 H),7.94(d,J=16.4Hz,1H),7.82(td,J=7.7,1.7Hz,1H),7.67(d,J=7.5Hz,2H),7.59(dd,J=18 .1,12.3Hz,2H),7.45(s,1H),7.34(t,J=8.0Hz,1H),7.28(dd,J=6.8,5.0Hz,1H),7.19–7.16( m,1H),7.07(d,J=7.9Hz,1H),2.15(d,J=7.1Hz,2H),2.06–2.02(m,1H),0.91(d,J=6.6Hz,6H). 13 C NMR(126MHz,DMSO-d6)δ171.36,155.33,150.02,142.32,140.86,137.35,135.39,133.76,130.38,130.12,129.69,1 25.90,124.19,124.09,123.12,122.97,122.18,121.49,120.34,118.67,112.45,46.05,25.96,22.73.HRMS(ESI)m / z calcd for C 25 H 24 N4OS[M+H]+429.1744; found,429.1740.

[0174] Example 13

[0175] To synthesize (E)-N-(3-((3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thio)phenyl)pivalamide, (E)-3-((3-(2-(pyridin-2-yl)vinyl)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-6-yl)thio)aniline and trimethylacetic acid were selected as raw materials, and the other embodiments were the same as those in Example 4;

[0176] The prepared compound was a light yellow solid with a yield of 54.5%;

[0177] The product H NMR spectrum is: 1 H NMR(500MHz,DMSO-d6)δ13.36(s,1H),9.98(s,1H),8.65(d,J=3.8Hz,1H),8.24 (d,J=8.5Hz,1H),7.98(d,J=16.4Hz,1H),7.85(t,J=6.9Hz,1H),7.74–7.69(m,3 H),7.68–7.58(m,3H),7.49(s,1H),7.37(t,J=8.0Hz,1H),7.32(dd,J=6.4,5.0 Hz,2H),7.21(d,J=8.5Hz,1H),7.10(d,J=7.6Hz,1H),2.21(s,2H),1.04(s,6H). 13 CNMR(126MHz,DMSO-d6)δ170.73,155.34,150.02,142.38,140.85,137.34,135.26,133.84,130.35,129.68,128.52,1 25.99,124.11,123.12,122.96,122.17,121.68,120.32,118.83,116.94,112.39,49.99,31.29,30.04.HRMS(ESI)m / z calcd for C 26 H 26 N4OS[M+H]+443.1900; found,443.1906.

[0178] Embodiment 14

[0179] To synthesize (E)-2-cyclopropyl-N-(3-((3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thio)phenyl)acetamide, (E)-3-((3-(2-(pyridin-2-yl)vinyl)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-6-yl)thio)aniline and cyclopropylacetic acid were selected as raw materials, and the other embodiments were the same as those in Example 4;

[0180] The prepared compound was a light yellow solid with a yield of 57.2%;

[0181] The product H NMR spectrum is: 1 H NMR (500MHz, DMSO-d6) δ13.11(s,1H),9.74(s,1H),8.44(d,J=4.0Hz,1H),8.03(d,J=8.5Hz,1H),7. 77(d,J=16.4Hz,1H),7.65(td,J=7.7,1.7Hz,1H),7.53–7.48(m,2H),7.42(dd,J=18.1,12.3Hz,2H), 7.29(s,1H),7.18(t,J=8.0Hz,1H),7.11(dd,J=6.7,4.9Hz,1H),7.01(dd,J=8.5,1.3Hz,1H),6.91(d ,J=7.9Hz,1H),2.01(d,J=7.0Hz,2H),0.91–0.84(m,1H),0.32–0.27(m,2H),-0.00(q,J=4.9Hz,2H). 13 C NMR(126MHz,DMSO-d6)δ171.47,155.35,150.02,142.39,140.92,137.32,135.39,133.81,130.36,129.71,125.95, 124.17,124.10,124.06,123.09,122.95,122.16,121.56,120.35,118.69,112.45,41.86,8.09,4.54.HRMS(ESI)m / z calcd for C 25 H 22 N4OS[M+H]+427.1587; found,427.1587.

[0182] Embodiment 15

[0183] Synthesis of (E)-2-cyclobutyl-N-(3-((3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thio)phenyl)acetamide: (E)-3-((3-(2-(pyridin-2-yl)vinyl)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-6-yl)thio)aniline and cyclobutylacetic acid were used as raw materials, and other embodiments were the same as those in Example 4;

[0184] The prepared compound was a light yellow solid with a yield of 66.8%;

[0185] The product H NMR spectrum is: 1H NMR (500MHz, DMSO-d6) δ13.28(s,1H),9.93(s,1H),8.61(d,J=4.1Hz,1H),8.20(d,J=8.5Hz,1H),7.94( d,J=16.4Hz,1H),7.81(td,J=7.7,1.4Hz,1H),7.67(d,J=7.5Hz,2H),7.60–7.55(m,2H),7.45(s,1H),7 .33(t,J=8.0Hz,1H),7.28(dd,J=7.0,5.1Hz,1H),7.17(d,J=8.4Hz,1H),7.07(d,J=7.7Hz,1H),2.64(d t,J=15.6,7.8Hz,1H),2.39(d,J=7.5Hz,2H),2.06–1.99(m,2H),1.86–1.78(m,2H),1.73–1.65(m,2H). 13 C NMR (126MHz, DMSO-d6) δ170.92,155.34,150.02,142.46,142.32,140.88,137.35,135.35,133.82,130.37,129.70,125. 91,124.15,124.11,123.12,122.97,122.17,121.48,120.35,118.63,112.41,43.81,32.79,28.09,18.59.HRMS(ESI)m / z calcd forC 26 H 24 N4OS[M+H]+441.1744; found,441.1746.

[0186] Example 16

[0187] Synthesis of (E)-2-cyclopentyl-N-(3-((3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thio)phenyl)acetamide: (E)-3-((3-(2-(pyridin-2-yl)vinyl)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-6-yl)thio)aniline and cyclopentylacetic acid were used as raw materials, and other embodiments were the same as those in Example 4;

[0188] The prepared compound was a light yellow solid with a yield of 64.7%;

[0189] The product H NMR spectrum is: 1H NMR (500MHz, DMSO-d6) δ13.28(s,1H),9.95(s,1H),8.61(d,J=4.0Hz,1H),8.20(d,J=8.5Hz,1H),7.94(d,J=16.4Hz ,1H),7.82(td,J=7.7,1.7Hz,1H),7.67(d,J=7.2Hz,2H),7.58(t,J=13.8Hz,2H),7.45(s,1H),7.33(t,J=8.0Hz,1H) ,7.28(dd,J=7.0,5.1Hz,1H),7.17(dd,J=8.5,1.2Hz,1H),7.07(d,J=7.7Hz,1H),2.27(d,J=7.4Hz,2H),2.20(dd,J= 14.9,7.5Hz,1H),1.72(dt,J=11.6,5.9Hz,2H),1.62–1.54(m,2H),1.52–1.47(m,2H),1.15(td,J=15.3,7.7Hz,2H). 13 C NMR (126MHz, DMSO-d6) δ171.59,155.33,150.02,142.46,142.32,140.92,137.35,135.36,133.79,130.37,129.69,125. 89,124.16,123.62,123.12,122.97,122.18,121.50,120.34,118.66,112.42,43.00,36.99,32.33,24.95.HRMS(ESI)m / z calcd for C 27 H 26 N4OS[M+H]+455.1900; found,455.1982.

[0190] Embodiment 17

[0191] To synthesize (E)-2-cyclohexyl-N-(3-((3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thio)phenyl)acetamide, (E)-3-((3-(2-(pyridin-2-yl)vinyl)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-6-yl)thio)aniline and cyclohexyl acetic acid were selected as raw materials, and the other embodiments were the same as those in Example 4;

[0192] The prepared compound was a light yellow solid with a yield of 58.5%;

[0193] The product H NMR spectrum is: 1H NMR (500MHz, DMSO-d6) δ13.27(s,1H),9.94(s,1H),8.61(d,J=4.3Hz,1H),8.20(d,J=8.5Hz,1H),7.94 (d,J=16.4Hz,1H),7.81(td,J=7.7,1.5Hz,1H),7.67(d,J=7.5Hz,2H),7.58(t,J=13.6Hz,2H),7.45(s, 1H),7.33(t,J=8.0Hz,1H),7.28(dd,J=7.0,5.1Hz,1H),7.17(d,J=8.5Hz,1H),7.07(d,J=7.8Hz,1H), 2.15(d,J=7.1Hz,2H),1.78–1.70(m,1H),1.66(d,J=6.9Hz,4H),1.26–1.05(m,4H),0.99–0.89(m,2H). 13 C NMR(126MHz,DMSO-d6)δ171.22,155.34,150.02,142.47,142.45,140.87,137.34,135.38,133.77,130.36,129.69,125.89, 124.18,124.10,123.12,122.96,122.18,121.48,120.35,118.65,112.47,44.72,35.16,32.96,26.27,26.03.HRMS(ESI)m / z calcdfor C 28 H 28 N4OS[M+H]+469.2057; found,469.1947.

[0194] Embodiment 18

[0195] To synthesize (E)-2-phenyl-N-(4-((3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thio)phenyl)acetamide, (E)-3-((3-(2-(pyridin-2-yl)vinyl)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-6-yl)thio)aniline and phenylacetic acid were selected as raw materials, and other embodiments were the same as those in Example 4;

[0196] The prepared compound was a light yellow solid with a yield of 62.5%;

[0197] The product H NMR spectrum is: 1H NMR (500MHz, DMSO-d6) δ13.28(s,1H),10.26(s,1H),8.61(d,J=4.2Hz,1H),8.20(d,J=8.5Hz,1 H),7.95(d,J=16.4Hz,1H),7.81(td,J=7.7,1.3Hz,1H),7.67(d,J=8.1Hz,2H),7.59(dd,J=18. 0,12.4Hz,2H),7.46(s,1H),7.35(t,J=8.0Hz,1H),7.31(d,J=4.3Hz,4H),7.28(dd,J=7.1,5.2 Hz,1H),7.23(dt,J=8.7,4.2Hz,1H),7.17(d,J=8.4Hz,1H),7.09(d,J=7.7Hz,1H),3.61(s,2H). 13 C NMR (126MHz, DMSO-d6) δ169.80,155.34,150.02,142.48,142.32,140.80,137.34,136.21,135.56,133.70,130.44,12 9.72,129.58,128.78,127.04,126.11,124.21,123.12,122.20,121.51,120.40,118.70,112.53,43.75.HRMS(ESI)m / z calcd for C 28 H 22 N4OS[M+H]+463.1587; found,463.1583.

[0198] Embodiment 19

[0199] To synthesize (E)-2-(2-methoxyphenyl)-N-(3-((3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thio)phenyl)acetamide, (E)-3-((3-(2-(pyridin-2-yl)vinyl)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-6-yl)thio)aniline and 2-methoxyphenylacetic acid were selected as raw materials, and the other embodiments were the same as those in Example 4;

[0200] The prepared compound was a light yellow solid with a yield of 65.5%;

[0201] The product H NMR spectrum is: 1H NMR (500MHz, DMSO-d6) δ13.28(s,1H),10.15(s,1H),8.63–8.58(m,1H),8.20(d,J=8.5Hz,1H),7.94(d ,J=16.4Hz,1H),7.82(td,J=7.7,1.8Hz,1H),7.67(d,J=7.9Hz,2H),7.60(dd,J=11.1,3.4Hz,2H),7.45 (s,1H),7.34(t,J=8.0Hz,1H),7.28(dd,J=7.3,4.9Hz,1H),7.23(s,1H),7.18(dd,J=7.7,5.6Hz,2H),7 .08(d,J=7.7Hz,1H),6.96(d,J=8.1Hz,1H),6.89(t,J=7.5Hz,1H),3.73(d,J=7.5Hz,3H),3.60(s,2H). 13 C NMR (126MHz, DMSO-d6) δ160.24,158.79,158.20,155.37,150.03,142.55,140.03,137.34,136.35,133.01,132.79,132.71,132.63,130.66 ,129.65,126.66,124.56,124.07,123.13,122.95,122.29,121.28,120.56,118.78,115.66,115.48,113.36,112.67,112.48.HRMS(ESI)m / z calcd for C 29 H 24 N4O2S[M+H]+493.1696; found,493.1696.

[0202] Embodiment 20

[0203] To synthesize (E)-2-(3-methoxyphenyl)-N-(3-((3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thio)phenyl)acetamide, (E)-3-((3-(2-(pyridin-2-yl)vinyl)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-6-yl)thio)aniline and 3-methoxyphenylacetic acid were selected as raw materials, and the other embodiments were the same as those in Example 4;

[0204] The prepared compound was a light yellow solid with a yield of 68.5%;

[0205] The product H NMR spectrum is: 1H NMR(500MHz,DMSO-d6)δ13.27(s,1H),10.21(s,1H),8.63–8.59(m,1H),8.20(d,J=8.5Hz,1H), 7.94(d,J=16.3Hz,1H),7.81(td,J=7.7,1.8Hz,1H),7.71–7.65(m,2H),7.63–7.57(m,2H),7.4 5(s,1H),7.34(t,J=8.0Hz,1H),7.28(ddd,J=7.5,4.7,1.1Hz,1H),7.25–7.20(m,2H),7.17(dd ,J=8.5,1.5Hz,1H),7.08(dt,J=8.1,1.1Hz,1H),6.90–6.85(m,2H),3.72(s,3H),3.53(s,2H). 13 C NMR (126MHz, DMSO-d6) δ170.19,158.53,155.35,150.04,142.48,142.32,140.87,137.36,135.50,133.75,130.58,130.44,129.7 2,128.11,126.09,124.19,124.12,123.14,122.98,122.21,121.53,120.39,118.70,114.22,112.48,55.49,42.87.HRMS(ESI)m / z calcd for C 29 H 24 N4O2S[M+H]+493.1696; found,493.1692.

[0206] Embodiment 21

[0207] To synthesize (E)-2-(4-methoxyphenyl)-N-(3-((3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thio)phenyl)acetamide, (E)-3-((3-(2-(pyridin-2-yl)vinyl)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-6-yl)thio)aniline and 4-methoxyphenylacetic acid were selected as raw materials, and the other embodiments were the same as those in Example 4;

[0208] The prepared compound was a light yellow solid with a yield of 56.5%;

[0209] The product H NMR spectrum is: 1H NMR(500MHz,DMSO-d6)δ13.20(s,1H),10.16(s,1H),8.53(dd,J=4.8,1.8Hz,1H),8.13(d,J=8.5Hz,1H) ,7.87(d,J=16.4Hz,1H),7.74(td,J=7.6,1.9Hz,1H),7.59(dd,J=4.6,2.8Hz,2H),7.55–7.48(m,2H),7. 38(d,J=1.5Hz,1H),7.27(t,J=8.0Hz,1H),7.23–7.19(m,1H),7.15(t,J=7.8Hz,1H),7.10(dd,J=8.5,1 .5Hz,1H),7.01(dt,J=7.8,1.3Hz,1H),6.82–6.78(m,2H),6.76–6.72(m,1H),3.65(s,3H),3.50(s,2H). 13 C NMR (126MHz, DMSO-d6) δ169.68,159.68,155.36,150.04,142.49,142.33,140.80,137.64,137.35,135.57,133.70,130.46,129.81,129. 73,126.12,124.22,124.13,123.13,122.97,122.21,121.80,121.52,120.41,118.72,115.38,112.44,55.43,43.81.HRMS(ESI)m / zcalcd for C 29 H 24 N4O2S[M+H]+493.1696; found,493.1697.

[0210] Embodiment 22

[0211] To synthesize (E)-N-(3-((3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thio)phenyl)-2-(o-tolyl)acetamide, (E)-3-((3-(2-(pyridin-2-yl)vinyl)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-6-yl)thio)aniline and 2-methylphenylacetic acid were selected as raw materials, and the other embodiments were the same as those in Example 4;

[0212] The prepared compound was a light yellow solid with a yield of 61.5%;

[0213] The product H NMR spectrum is: 1H NMR (500MHz, DMSO-d6) δ13.28(s,1H),10.26(s,1H),8.60(d,J=4.2Hz,1H),8.20(d,J=8.5Hz,1H), 7.93(d,J=16.3Hz,1H),7.81(td,J=7.7,1.5Hz,1H),7.66(d,J=7.5Hz,2H),7.61(d,J=8.3Hz,1H),7 .56(d,J=16.4Hz,1H),7.45(s,1H),7.34(t,J=8.0Hz,1H),7.28(dd,J=7.0,5.1Hz,1H),7.22–7.19 (m,1H),7.17(d,J=8.7Hz,1H),7.15–7.11(m,3H),7.08(d,J=7.8Hz,1H),3.65(s,2H),2.26(s,3H). 13 C NMR (126MHz, DMSO-d6) δ169.75,155.34,150.02,142.46,142.31,140.82,137.35,137.11,135.51,134.89,133.71,130.44,130.34,129.7 0,127.27,127.18,126.22,126.08,124.19,124.11,123.12,122.97,122.20,121.55,120.38,118.72,112.50,41.36,19.84.HRMS(ESI)m / z calcd for C 29 H 24 N4OS[M+H]+477.1744; found,477.1740.

[0214] Embodiment 23

[0215] To synthesize (E)-N-(3-((3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thio)phenyl)-2-(m-tolyl)acetamide, (E)-3-((3-(2-(pyridin-2-yl)vinyl)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-6-yl)thio)aniline and 3-methylphenylacetic acid were selected as raw materials, and the other embodiments were the same as those in Example 4;

[0216] The prepared compound was a light yellow solid with a yield of 57.2%;

[0217] The product H NMR spectrum is: 1H NMR(600MHz,DMSO-d6)δ13.24(s,1H),10.22(s,1H),8.58(s,1H),8.17(d,J=8.3Hz,1H) ,7.91(d,J=16.6Hz,1H),7.78(t,J=7.3Hz,1H),7.64(d,J=11.4Hz,2H),7.56(dd,J=22.9 ,12.1Hz,2H),7.43(s,1H),7.32(t,J=7.9Hz,1H),7.26(d,J=6.3Hz,1H),7.15(dd,J=17 .1,8.6Hz,2H),7.07(d,J=13.7Hz,3H),7.02(d,J=7.1Hz,1H),3.54(s,2H),2.25(s,3H). 13 C NMR(151MHz,DMSO-d6)δ169.81,155.30,150.02,142.42,142.26,140.77,137.77,137.39,136.04,135.48,133.67,130.40,130.21,130.0 8,129.75,129.58,128.64,124.15,123.14,122.96,122.20,122.08,121.61,121.39,120.35,118.78,118.57,43.68,29.46.HRMS(ESI)m / z calcd for C 29 H 24 N4OS[M+H] + 477.1744; found, 477.1742.

[0218] Embodiment 24

[0219] To synthesize (E)-2-(4-methylphenyl)-N-(3-((3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thio)phenyl)acetamide, (E)-3-((3-(2-(pyridin-2-yl)vinyl)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-6-yl)thio)aniline and 4-methylphenylacetic acid were selected as raw materials, and the other embodiments were the same as those in Example 4;

[0220] The prepared compound was a light yellow solid with a yield of 58.4%;

[0221] The product H NMR spectrum is: 1H NMR (500MHz, DMSO-d6) δ13.34(s,1H),10.37(s,1H),8.61(d,J=4.4Hz,1H),8.19(d,J=8.5Hz,1H),7.93( dd,J=16.4,4.6Hz,1H),7.81(t,J=7.6Hz,1H),7.66(d,J=7.8Hz,1H),7.61(d,J=8.3Hz,1H),7.56(dd,J= 16.4,5.4Hz,1H),7.45(s,1H),7.34(t,J=8.0Hz,1H),7.28(dd,J=6.8,5.4Hz,1H),7.19(d,J=7.9Hz,2H) ,7.17–7.14(m,1H),7.11(d,J=7.8Hz,2H),7.07(d,J=9.0Hz,1H),5.29(s,1H),3.57(s,2H),2.26(s,3H). 13 C NMR (126MHz, DMSO-d6) δ170.03,155.34,150.02,140.88,137.35,136.03,135.43,133.70,133.20,130.40,129.66,129.44,12 9.31,126.08,124.15,123.12,122.96,122.19,121.56,120.33,119.15,118.72,116.92,114.03,43.33,21.10.HRMS(ESI)m / z calcd for C 29 H 24 N4OS[M+H]+477.1744; found,477.1745.

[0222] Embodiment 25

[0223] To synthesize (E)-N-(3-((3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thio)phenyl)-2-(p-tolyl)acetamide, (E)-3-((3-(2-(pyridin-2-yl)vinyl)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-6-yl)thio)aniline and 2-trifluoromethylphenylacetic acid were selected as raw materials, and the other embodiments were the same as those in Example 4;

[0224] The prepared compound was a light yellow solid with a yield of 62.5%;

[0225] The product H NMR spectrum is: 1H NMR(500MHz,DMSO-d6)δ13.28(s,1H),10.32(s,1H),8.61(d,J=4.0Hz,1H),8.2 0(d,J=8.5Hz,1H),7.94(d,J=16.4Hz,1H),7.82(td,J=7.7,1.7Hz,1H),7.71–7. 62(m,4H),7.58(s,2H),7.49(dd,J=13.7,7.3Hz,3H),7.35(t,J=8.0Hz,1H),7.2 8(dd,J=7.1,5.0Hz,1H),7.19–7.16(m,1H),7.09(d,J=7.8Hz,1H),3.90(s,2H). 13 C NMR (126MHz, DMSO-d6) δ168.72,150.03,140.72,137.35,135.62,134.63,133.93,133.62,132.71,131.86,130.48,129.70,128.48,127.88 ,127.81,126.14,126.10,126.06,125.36,124.25,124.09,123.13,122.98,122.22,121.44,120.92,118.65,113.25,39.48.HRMS(ESI)m / z calcd for C 29 H 24 N4OS[M+H]+531.1461; found,531.1460.

[0226] Embodiment 26

[0227] To synthesize (E)-N-(3-((3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thio)phenyl)-2-(3-(trifluoromethyl)phenyl)acetamide, (E)-3-((3-(2-(pyridin-2-yl)vinyl)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-6-yl)thio)aniline and 3-trifluoromethylphenylacetic acid were used as raw materials, and other embodiments were the same as those in Example 4;

[0228] The prepared compound was a light yellow solid with a yield of 59.5%;

[0229] The product H NMR spectrum is: 1H NMR(500MHz,DMSO-d6)δ13.28(s,1H),10.32(s,1H),8.61(d,J=4.2Hz,1H),8 .20(d,J=8.5Hz,1H),7.96(s,1H),7.81(td,J=7.7,1.6Hz,1H),7.68–7.64(m ,3H),7.63–7.54(m,5H),7.47(s,1H),7.35(t,J=8.0Hz,1H),7.28(dd,J=7.3 ,4.9Hz,1H),7.17(dd,J=8.5,1.2Hz,1H),7.10(d,J=7.9Hz,1H),3.76(s,2H). 13 C NMR (126MHz, DMSO-d6) δ169.22,155.33,150.02,142.46,140.63,137.51,137.34,135.69,133.96,133.56,130.47,129.77,129.70,129.53 ,129.28,126.34,126.14,125.81,124.29,123.86,123.65,123.12,122.97,122.22,121.47,120.40,118.71,112.66,43.00.HRMS(ESI)m / z calcd for C 29 H 24 N4OS[M+H]+531.1461; found,531.1469.

[0230] Embodiment 27

[0231] To synthesize (E)-N-(3-((3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thio)phenyl)-2-(4-(trifluoromethyl)phenyl)acetamide, (E)-3-((3-(2-(pyridin-2-yl)vinyl)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-6-yl)thio)aniline and 4-trifluoromethylphenylacetic acid were used as raw materials, and other embodiments were the same as those in Example 4;

[0232] The prepared compound was a light yellow solid with a yield of 63.5%;

[0233] The product H NMR spectrum is: 1H NMR (500MHz, DMSO-d6) δ13.29(s,1H),10.36(s,1H),8.61(d,J=4.0Hz,1H),8.21(d,J= 8.5Hz,1H),7.95(d,J=16.4Hz,1H),7.81(td,J=7.7,1.7Hz,1H),7.68(d,J=8.2Hz,3H) ,7.60(d,J=10.1Hz,2H),7.56–7.52(m,3H),7.47(s,1H),7.35(t,J=8.0Hz,1H),7.28( dd,J=7.2,4.9Hz,1H),7.17(dd,J=8.5,1.1Hz,1H),7.10(d,J=7.9Hz,1H),3.75(s,2H). 13 C NMR (126MHz, DMSO-d6) δ155.33,150.02,142.47,142.31,141.00,140.64,137.34,135.69,133.59,132.52,131.99,131.92,130.55 ,130.46,129.72,129.28,126.15,125.59,124.29,123.12,122.97,122.22,121.47,120.42,118.70,112.66,43.28.HRMS(ESI)m / z calcd for C 29 H 24 N4OS[M+H]+531.1461; found,531.1460.

[0234] Embodiment 28

[0235] To synthesize (E)-2-(2-fluorophenyl)-N-(3-((3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thio)phenyl)acetamide, (E)-3-((3-(2-(pyridin-2-yl)vinyl)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-6-yl)thio)aniline and o-fluorophenylacetic acid were selected as raw materials, and other embodiments were the same as those in Example 4;

[0236] The prepared compound was a light yellow solid with a yield of 66.5%;

[0237] The product H NMR spectrum is: 1H NMR(500MHz,DMSO-d6)δ13.27(s,1H),10.31(s,1H),8.60(d,J=4.3Hz,1H),8.20( d,J=8.5Hz,1H),7.93(d,J=16.4Hz,1H),7.81(t,J=7.5Hz,1H),7.66(d,J=7.1Hz, 2H),7.58(dd,J=16.5,12.5Hz,2H),7.46(s,1H),7.35(dd,J=9.4,6.5Hz,2H),7.2 9(dd,J=13.6,8.4Hz,2H),7.19–7.13(m,3H),7.09(d,J=7.7Hz,1H),3.70(s,2H). 13 C NMR (126MHz, DMSO-d6) δ168.75,162.08,160.14,155.34,150.02,142.47,142.31,140.72,137.35,135.60,133.65,132.49,130.47,12 9.71,129.33,126.10,124.71,124.23,123.24,123.12,122.97,122.21,121.47,120.39,118.67,115.56,112.56,36.75.HRMS(ESI)m / z calcd for C 29 H 24 N4OS[M+H]+481.1493; found,481.1496.

[0238] Embodiment 29

[0239] To synthesize (E)-2-(4-fluorophenyl)-N-(3-((3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thio)phenyl)acetamide, (E)-3-((3-(2-(pyridin-2-yl)vinyl)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-6-yl)thio)aniline and p-fluorophenylacetic acid were selected as raw materials, and other embodiments were the same as those in Example 4;

[0240] The prepared compound was a light yellow solid with a yield of 61.2%;

[0241] The product H NMR spectrum is: 1H NMR(500MHz,DMSO-d6)δ13.28(s,1H),10.27(s,1H),8.61(d,J=3.9Hz,1H), 8.20(d,J=8.5Hz,1H),7.94(d,J=16.3Hz,1H),7.81(t,J=7.0Hz,1H),7.68–7 .65(m,2H),7.60(d,J=10.5Hz,2H),7.46(s,1H),7.35–7.32(m,3H),7.30–7. 26(m,1H),7.14(dd,J=15.5,6.6Hz,3H),7.09(d,J=7.7Hz,1H),3.61(s,2H). 13 C NMR (126MHz, DMSO-d6) δ169.71,162.56,160.63,155.34,150.02,142.31,140.75,137.34,135.59,133.65,132.35,131.51,13 0.44,129.71,126.10,124.23,124.11,123.12,122.96,122.20,121.49,120.40,118.69,115.55,112.57,42.69.HRMS(ESI)m / z calcd for C 29 H 24 N4OS[M+H]+481.1493; found,481.1495.

[0242] Embodiment 30

[0243] To synthesize (E)-2-(2-chlorophenyl)-N-(3-((3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thio)phenyl)acetamide, (E)-3-((3-(2-(pyridin-2-yl)vinyl)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-6-yl)thio)aniline and 2-chlorophenylacetic acid were selected as raw materials, and the other embodiments were the same as those in Example 4;

[0244] The prepared compound was a light yellow solid with a yield of 65.8%;

[0245] The product H NMR spectrum is: 1H NMR(500MHz,DMSO-d6)δ13.28(s,1H),10.32(s,1H),8.61(d,J=4.0Hz,1H),8.20(d, J=8.5Hz,1H),7.94(d,J=16.4Hz,1H),7.81(td,J=7.7,1.6Hz,1H),7.67(d,J=4.1Hz ,2H),7.62–7.56(m,2H),7.46(s,1H),7.44–7.38(m,2H),7.35(t,J=8.0Hz,1H),7.2 9(dd,J=5.9,3.4Hz,3H),7.18(d,J=8.4Hz,1H),7.09(d,J=7.7Hz,1H),3.81(s,2H). 13 C NMR (126MHz, DMSO-d6) δ168.61,155.36,150.02,142.47,142.32,140.77,137.32,135.60,134.19,134.13,133.65,132.66,130.44,12 9.72,129.45,129.08,127.51,126.06,124.24,124.11,123.09,122.95,122.18,121.50,120.41,118.67,112.58,41.22.HRMS(ESI)m / z calcd for C 28 H 21 ClN4OS[M+H]+497.1197; found,497.1198.

[0246] Embodiment 31

[0247] To synthesize (E)-2-(3-chlorophenyl)-N-(3-((3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thio)phenyl)acetamide, (E)-3-((3-(2-(pyridin-2-yl)vinyl)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-6-yl)thio)aniline and 3-chlorophenylacetic acid were selected as raw materials, and the other embodiments were the same as those in Example 4;

[0248] The prepared compound was a light yellow solid with a yield of 66.5%;

[0249] The product H NMR spectrum is: 1H NMR (500MHz, DMSO-d6) δ13.28(s,1H),10.30(s,1H),8.61(d,J=4.7Hz,1H),8.20(d,J= 8.5Hz,1H),7.94(d,J=16.4Hz,1H),7.81(td,J=7.7,1.8Hz,1H),7.68–7.65(m,2H),7.6 2–7.54(m,2H),7.46(s,1H),7.38(s,1H),7.35(dd,J=7.9,2.1Hz,1H),7.34–7.31(m,1 H),7.30–7.25(m,2H),7.17(dd,J=8.5,1.4Hz,1H),7.09(d,J=7.9Hz,1H),3.65(s,2H). 13 C NMR (126MHz, DMSO-d6) δ169.23,155.36,150.02,142.48,142.32,140.66,138.59,137.32,135.64,133.63,133.28,130.57,130.44,12 9.73,129.55,128.42,127.04,126.16,124.25,124.11,123.09,122.95,122.19,121.54,120.42,118.73,112.61,43.06.HRMS(ESI)m / z calcd for C 28 H 21 ClN4OS[M+H]+497.1197; found,497.1198.

[0250] Embodiment 32

[0251] To synthesize (E)-2-(4-chlorophenyl)-N-(3-((3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thio)phenyl)acetamide, (E)-3-((3-(2-(pyridin-2-yl)vinyl)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-6-yl)thio)aniline and 4-chlorophenylacetic acid were selected as raw materials, and the other embodiments were the same as those in Example 4;

[0252] The prepared compound was a light yellow solid with a yield of 58.5%;

[0253] The product H NMR spectrum is: 1H NMR(500MHz,DMSO-d6)δ13.28(s,1H),10.28(s,1H),8.61(d,J=4.1Hz,1H),8.20(d, J=8.5Hz,1H),7.94(d,J=16.3Hz,1H),7.81(td,J=7.7,1.7Hz,1H),7.66(d,J=9.2Hz, 2H),7.60–7.55(m,2H),7.46(s,1H),7.37(d,J=8.4Hz,2H),7.33(t,J=8.5Hz,3H),7. 28(dd,J=7.1,5.0Hz,1H),7.17(d,J=8.4Hz,1H),7.09(d,J=7.8Hz,1H),3.62(s,2H). 13 C NMR (126MHz, DMSO-d6) δ169.44,155.34,150.02,142.47,142.31,140.70,137.34,135.63,135.17,133.62,131.79,131.52,13 0.45,129.72,128.69,126.12,124.26,124.10,123.12,122.97,122.21,121.47,120.41,118.69,112.61,42.84.HRMS(ESI)m / z calcd for C 28 H 21 ClN4OS[M+H]+497.1197; found,497.1204.

[0254] Embodiment 33

[0255] The synthetic reaction formula is as follows:

[0256]

[0257] The synthesis steps are as follows:

[0258] (1) To a mixture of 2 g (8.97 mmol) of 6-iodo-1H-indazole and 0.63 g (5.09 mmol) of 3-aminothiophenol in dry 1,4-dioxane, 0.2 g (0.23 mmol) of tris(dibenzylideneacetone)dipalladium, 0.5 g (0.87 mmol) of 4,5-bis(diphenylphosphine)-9,9-dimethylxanthene and 1.28 g (9.28 mmol) of potassium carbonate were added, and the mixture was stirred at 80° C. under an argon atmosphere for 14 h. The solvent was evaporated and diluted with ethyl acetate, and then washed with water and brine; the organic phase was evaporated, eluted with 10% to 30% ethyl acetate by volume in petroleum ether, chromatographed, and purified to obtain 1.6 g of the intermediate 3-((1H-indazol-6-yl)thio)aniline as a yellow solid, with a yield of 71%;

[0259] (2) 1.22 g (7.91 mmol) of 3-((1H-indazol-6-yl)thio)aniline solution was added to 20 mL of dichloromethane, 3-fluorophenylacetic acid, 3.78 g (10 mmol) of 2-(7-azobenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate and 1.71 g (13.27 mmol) of N,N-diisopropylethylamine were added, and the resulting mixture was stirred at room temperature for 8 h; then diluted with 50 mL of ethyl acetate and washed three times with 100 mL of water, and then washed with The mixture was washed with 100 mL of brine, the organic layer was dried over anhydrous sodium sulfate and concentrated, and the residue was diluted with 20 mL of dichloromethane and 4 mL of trifluoroacetic acid; the reaction mixture was stirred at room temperature for 4 h, and then the pH value was adjusted to 12 with saturated sodium bicarbonate, the mixture was extracted with 50 mL of ethyl acetate, washed twice with 50 mL of water, and then washed with 50 mL of brine, the organic layer was dried over sodium sulfate, then filtered and concentrated, and eluted with 0-5% methanol in dichloromethane on a silica gel column, chromatographed, and purified to obtain 1.8 g of N-(3-((1H-indazol-6-yl)thio)phenyl)-2-(2-fluorophenyl)acetamide as a yellow solid in a yield of 72%;

[0260] (3) Add 1.8 g (4.7 mmol) of N-(3-((1H-indazol-6-yl)thio)phenyl)-2-(2-fluorophenyl)acetamide to 10 mL of anhydrous N,N-dimethylformamide (10 mL) solution, then add 0.51 g (12.74 mmol) of sodium hydroxide, and stir the mixture at 0°C. Add 12.08 g (47.74 mmol) of iodine to 5 mL of anhydrous N,N-dimethylformamide to form a solution, mix the solution with the previous solution, and stir at room temperature for 4 h. LC-MS is used to detect the end point of the reaction. After the reaction is completed, the solvent is dried by spin drying, extracted with 100 mL of ethyl acetate, washed twice with 100 mL of water, and then washed with 100 mL of saturated brine. The organic layer is dried by spin drying, mixed, and eluted with 0-30% by volume ethyl acetate in petroleum ether on a silica gel column, chromatographed, and purified to obtain 1.8 g 2-(2-Fluorophenyl)-N-(3-((3-iodo-1H-indazol-6-yl)thio)phenyl)acetamide yellow crystals, yield 75%;

[0261] (4) To a mixture of 100 mg (0.21 mmol) of 2-(2-fluorophenyl)-N-(3-((3-iodo-1H-indazol-6-yl)thio)phenyl)acetamide and 30 mg (0.24 mmol) of phenylboronic acid in dry N,N-dimethylformamide, 11.5 mg (0.01 mmol) of tetrakis(triphenylphosphine)palladium and 27.5 mg (0.2 mmol) of potassium carbonate were added, and the mixture was stirred at 80° C. under an argon atmosphere for 14 h; the solvent was evaporated and diluted with ethyl acetate, then washed with water and brine, the organic phase was evaporated, eluted with 10% to 30% ethyl acetate in petroleum ether on a silica gel column, chromatographed, and purified to obtain 2-(2-fluorophenyl)-N-(3-((3-phenyl-1H-indazol-6-yl)thio)phenyl)acetamide;

[0262] 60 mg of the compound was prepared as a light yellow solid with a yield of 66%;

[0263] The product H NMR spectrum is: 1 H NMR (500MHz, DMSO-d6) δ13.30(s,1H),10.46(s,1H),8.06(d,J=8.5Hz,1H),7.97(d,J=7.7Hz,2H),7.70(s,1H),7.62(d,J=8.1Hz,1H),7.52(t,J=7.6 Hz,2H),7.48(s,1H),7.42(d,J=7.4Hz,1H),7.38–7.34(m,2H),7.31–7.27 (m,1H),7.15(dd,J=11.3,6.6Hz,3H),7.09(d,J=7.8Hz,1H),3.72(s,2H). 13C NMR (126MHz, DMSO-d6) δ168.78,162.09,160.15,143.86,142.57,140.78,135.52,133.45,132.47,130.42,129.38,129.29 ,128.33,127.22,126.15,124.68,124.12,123.31,122.18,121.62,119.65,118.73,115.55,112.56,36.74.HRMS(ESI)m / z calcd for C 27 H 20 FN3OS[M+H] + 454.1384; found, 454.1386.

[0264] Embodiment 34

[0265] To synthesize 2-(2-fluorophenyl)-N-(3-((3-(p-tolyl)-1H-indazol-6-yl)thio)phenyl)acetamide, 2-(2-fluorophenyl)-N-(3-((3-iodo-1H-indazol-6-yl)thio)phenyl)acetamide and p-methylphenylboronic acid were selected as raw materials, and other embodiments were the same as those in Example 32;

[0266] The prepared compound was a light yellow solid with a yield of 53.5%;

[0267] The product H NMR spectrum is: 1 H NMR (500MHz, DMSO-d6) δ13.17(s,1H),10.29(s,1H),8.04(d,J=8.6Hz,1H),7.86(d,J=8.0Hz,2H),7.66(s,1H),7.60( d,J=8.3Hz,1H),7.47(s,1H),7.39–7.30(m,5H),7.18–7.12(m,3H),7.09(d,J=7.8Hz,1H),3.71(s,2H),2.37(s,3H). 13 C NMR(126MHz,DMSO-d6)δ168.73,162.09,143.97,142.53,140.70,137.67,135.72,133.27,132.47,131.03,130.43,129.95,12 9.32,127.13,126.05,124.69,124.08,123.25,122.25,121.46,119.69,118.64,115.55,112.64,36.75,21.33.HRMS(ESI)m / z calcd forC28 H 22 FN3OS[M+H] + 468.1540; found, 468.1545.

[0268] Embodiment 35

[0269] To synthesize 2-(2-fluorophenyl)-N-(3-((3-(4-(trifluoromethyl)phenyl)-1H-indazol-6-yl)thio)phenyl)acetamide, 2-(2-fluorophenyl)-N-(3-((3-iodo-1H-indazol-6-yl)thio)phenyl)acetamide and 4-trifluoromethylphenylboronic acid were selected as raw materials, and other embodiments were the same as those in Example 32;

[0270] The prepared compound was a light yellow solid with a yield of 62.5%;

[0271] The product H NMR spectrum is: 1 H NMR (500MHz, DMSO-d6) δ13.46(s,1H),10.30(s,1H),8.21(d,J=8.1Hz,2H),8.12(d,J=8.6Hz,1H),7.86(d,J=8.2Hz,2H),7.69(s,1H),7.60(d,J=8 .6Hz,1H),7.50(s,1H),7.36(t,J=7.9Hz,2H),7.30(d,J=7.2Hz,1H),7.1 9(d,J=8.6Hz,1H),7.16–7.13(m,2H),7.11(d,J=7.9Hz,1H),3.70(s,2H). 13 C NMR (126MHz, DMSO-d6) δ168.75,162.08,160.14,142.66,142.39,140.74,137.77,135.32,133.99,132.47,130.50,129.33,12 7.67,126.33,126.30,126.27,124.70,124.52,123.23,122.00,121.73,119.62,118.82,115.55,112.54,36.76.HRMS(ESI)m / z calcd for C 25 H 18 FN5OS[M+H] + 552.1258; found, 552.1259.

[0272] Embodiment 37

[0273] To synthesize 2-(2-fluorophenyl)-N-(3-((3-(pyridin-3-yl)-1H-indazol-6-yl)thio)phenyl)acetamide, 2-(2-fluorophenyl)-N-(3-((3-iodo-1H-indazol-6-yl)thio)phenyl)acetamide and pyridin-3-ylboronic acid were selected as raw materials, and other embodiments were the same as those in Example 32;

[0274] The prepared compound was a light yellow solid with a yield of 62.5%;

[0275] The product H NMR spectrum is: 1 H NMR (500MHz, DMSO-d6) δ13.42(s,1H),10.32(s,1H),9.18(s,1H),8.62(d,J=3.3Hz,1H),8.35(d,J=7.5Hz,1H),8.11(d,J=8.4Hz,1H ),7.70(s,1H),7.61(d,J=7.6Hz,1H),7.53(dd,J=17.7,10.7Hz,2H),7.39–7.27(m,3H),7.14(dd,J=27.6,7.9Hz,4H),3.71(s,2H). 13 C NMR(126MHz,DMSO-d6)δ168.76,162.09,149.28,147.90,142.53,141.25,140.74,135.34,134.42,134.00,132.47,130.49,12 9.71,129.32,126.36,124.69,124.52,124.36,123.24,122.04,121.77,119.66,118.82,115.55,112.44,36.76.HRMS(ESI)m / z calcd for C 26 H 19 FN4OS[M+H] + 455.1336; found, 455.1338.

[0276] Embodiment 37

[0277] To synthesize 2-(2-fluorophenyl)-N-(3-((3-(pyridin-4-yl)-1H-indazol-6-yl)thio)phenyl)acetamide, 2-(2-fluorophenyl)-N-(3-((3-iodo-1H-indazol-6-yl)thio)phenyl)acetamide and pyridin-4-ylboronic acid were selected as raw materials, and the other embodiments were the same as those in Example 32;

[0278] The prepared compound was a light yellow solid with a yield of 68.5%;

[0279] The product H NMR spectrum is: 1 H NMR (500MHz, DMSO-d6) δ13.56(s,1H),10.32(s,1H),8.69(d,J=5.9Hz,2H),8.18(d,J=8.6Hz,1H),7.98(d,J=5.9Hz,2H),7.70(s,1H),7.61(d, J=8.3Hz,1H),7.50(s,1H),7.36(t,J=8.0Hz,2H),7.33–7.28(m,2H),7. 20(d,J=8.6Hz,1H),7.16–7.15(m,1H),7.14–7.12(m,1H),3.71(s,2H). 13 C NMR (126MHz, DMSO-d6) δ168.76,162.09,160.79,160.15,151.14,150.76,142.70,140.76,135.19,134.18,132.47,130.52,12 9.33,128.29,127.82,126.43,124.67,122.00,121.28,119.71,118.87,115.92,115.63,115.38,112.50,36.76.HRMS(ESI)m / z calcd for C 26 H 19 FN4OS[M+H] + 455.1336; found, 455.1352.

[0280] Embodiment 38

[0281] To synthesize 2-(2-fluorophenyl)-N-(3-((3-(pyrimidin-2-yl)-1H-indazol-6-yl)thio)phenyl)acetamide, 2-(2-fluorophenyl)-N-(3-((3-iodo-1H-indazol-6-yl)thio)phenyl)acetamide and pyrimidin-2-ylboronic acid were selected as raw materials, and other embodiments were the same as those in Example 32;

[0282] The prepared compound was a light yellow solid with a yield of 54.5%;

[0283] The product H NMR spectrum is: 1H NMR (500MHz, DMSO-d6) δ13.59(s,1H),10.31(s,1H),9.38(s,2H),9.23(s,1H),8.18(d,J=8.5Hz,1H),7.71(d,J=2.0Hz,1H),7 .63(d,J=1.4Hz,2H),7.57(d,J=2.7Hz,2H),7.51(s,1H),7.37(s,2H),7.31–7.28(m,1H),7.16(d,J=1.3Hz,1H),3.71(s,2H). 13 C NMR (126MHz, DMSO) δ168.78,162.10,157.92,154.76,142.50,140.77,138.44,135.13,134.53,133.63,132.82,132. 53,132.01,130.54,129.28,128.00,126.57,124.53,122.05,119.62,118.94,115.40,112.30,36.76.HRMS(ESI)m / z calcd forC 25 H 18 FN5OS[M+H] + 456.1245; found, 456.1245.

[0284] Embodiment 39

[0285] To synthesize 2-(2-fluorophenyl)-N-(3-((3-(2-fluoropyridin-3-yl)-1H-indazol-6-yl)thio)phenyl)acetamide, 2-(2-fluorophenyl)-N-(3-((3-iodo-1H-indazol-6-yl)thio)phenyl)acetamide and (2-fluoropyridin-3-yl)boric acid were selected as raw materials, and other embodiments were the same as those in Example 32;

[0286] The prepared compound was a light yellow solid with a yield of 63.5%;

[0287] The product H NMR spectrum is: 1 H NMR (500MHz, DMSO-d6) δ13.54(s,1H),10.30(s,1H),8.35(dd,J=14.8,5.7Hz,2H),7.82(dd,J=8.6,2.6Hz,1H),7.68(s, 1H),7.61(d,J=8.3Hz,1H),7.55–7.49(m,2H),7.38–7.28(m,3H),7.18–7.14(m,3H),7.10(d,J=7.8Hz,1H),3.71(s,2H). 13C NMR (126MHz, DMSO-d6) δ168.75,162.09,161.10,160.15,159.20,147.70,142.15,141.97,140.74,135.37,134.04,132.48,130.4 9,129.33,126.31,124.70,124.26,123.24,123.04,122.16,121.71,120.41,118.80,115.55,112.39,36.75.HRMS(ESI)m / zcalcd for C 26 H 18 F2N4OS[M+H] + 473.1242; found, 473.1242.

[0288] Embodiment 40

[0289] To synthesize N-(3-((3-(1H-pyrazol-4-yl)-1H-indazol-6-yl)thio)phenyl)-2-(2-fluorophenyl)acetamide, 2-(2-fluorophenyl)-N-(3-((3-iodo-1H-indazol-6-yl)thio)phenyl)acetamide and (1H-pyrazol-4-yl)boric acid were selected as raw materials, and other embodiments were the same as those in Example 32;

[0290] The prepared compound was a light yellow solid with a yield of 49.5%;

[0291] The product H NMR spectrum is: 1 H NMR (500MHz, DMSO-d6) δ13.28(s,1H),10.30(s,1H),8.61(d,J=4.7Hz,1H),8.20(d,J= 8.5Hz,1H),7.94(d,J=16.4Hz,1H),7.81(td,J=7.7,1.8Hz,1H),7.68–7.65(m,2H),7.6 2–7.54(m,2H),7.46(s,1H),7.38(s,1H),7.35(dd,J=7.9,2.1Hz,1H),7.34–7.31(m,1 H),7.30–7.25(m,2H),7.17(dd,J=8.5,1.4Hz,1H),7.09(d,J=7.9Hz,1H),3.65(s,2H). 13C NMR (126MHz, DMSO-d6) δ169.23,155.36,150.02,142.48,142.32,140.66,138.59,137.32,135.64,133.63,133.28,130.57,130.44,12 9.73,129.55,128.42,127.04,126.16,124.25,124.11,123.09,122.95,122.19,121.54,120.42,118.73,112.61,43.06.HRMS(ESI)m / z calcd for C 28 H 21 ClN4OS[M+H] + 497.1197; found, 497.1198.

[0292] Embodiment 41

[0293] Synthesis of 2-(2-fluorophenyl)-N-(3-((3-(6-(4-methylpiperazin-1-yl)pyridin-3-yl)-1H-indazol-6-yl)thio)phenyl)acetamide Select 2-(2-fluorophenyl)-N-(3-((3-iodo-1H-indazol-6-yl)thio)phenyl)acetamide and 2-(4-methylpiperazin-1-yl)pyridine-5-boronic acid pinacol ester as raw materials, and other implementation methods are the same as Example 32;

[0294] The prepared compound was a light yellow solid with a yield of 55.5%;

[0295] The product H NMR spectrum is: 1 H NMR(500MHz,DMSO-d6)δ13.00(s,1H),10.27(s,1H),8.12(d,J=2.0Hz,1H),8.05(s ,1H),7.72(dd,J=8.3,4.5Hz,2H),7.58(dd,J=8.8,2.1Hz,1H),7.53(s,1H),7.33( dd,J=8.0,4.1Hz,2H),7.29(s,2H),7.17–7.11(m,2H),6.95(d,J=8.4Hz,1H),6.82 (d,J=8.8Hz,1H),3.68(s,2H),3.51–3.46(m,4H),2.39–2.36(m,4H),2.21(s,3H). 13C NMR (126MHz, DMSO-d6) δ168.65,162.07,160.13,158.43,147.84,140.86,139.62,138.74,135.61,134.11,133.63,132.44,131.42,129. 30,125.01,124.68,123.26,123.13,122.90,122.31,122.01,119.21,115.55,111.69,106.38,54.86,46.28,44.96,36.70.HRMS(ESI)m / z calcd for C 31 H 29 FN6OS[M+H] + 531.2337; found, 553.2187.

[0296] Table 1 Aryl indazole ring compounds prepared in Examples 1-41

[0297]

[0298]

[0299]

[0300]

[0301] The properties of the compounds prepared in Examples 1-41 were tested as follows:

[0302] The inhibitory effects of the compounds prepared in Examples 1-41 on BaF3-TEL-VEGFR2 cells and parental BaF3 cells.

[0303] Parental BaF3 cells were grown in RPMI 1640 medium (Corning, USA) supplemented with 100 ng / mL IL-3, while Tel-VEGFR2-BaF3 cells were cultured in the same medium without IL-3. All cell lines were incubated in 96-well culture plates at 37°C and 5% CO2, with 1500-3000 cells per well. Serial dilutions of compounds were added to the wells, and cell proliferation was assessed after 72 hours. Cell viability was determined using a cell counting kit-8 (MedChemExpress, China) according to the manufacturer's instructions, and absorbance was measured at 450 nm using a microplate reader (iMARK, Bio-Rad). The data were normalized to a control group treated with DMSO and expressed as the average of three independent measurements. Dose-response curves were generated using Prism7.0 (GraphPad Software, San Diego, USA).

[0304] Table 2 Inhibitory activity of aryl indazole compounds prepared in Examples 1-40 on BaF3-TEL-VEGFR2 cells and parental BaF3 cells 50 :(Level 1: 0-1nM, Level 2: 1-10nM, Level 3: 10-100nM, Level 4: 100-1000nM, Level 5: 1000-10000nM, Level 6: >10000nM)

[0305]

[0306]

[0307] Industrial Applicability

[0308] The present invention provides a novel kinase inhibitor compound, which can be used to reduce or inhibit VEGFR2 kinase activity in cells or subjects, and / or prevent or treat VEGFR2 activity-related disorders in subjects. Therefore, it can be prepared into corresponding drugs, which are suitable for industrial applications.

[0309] Although the present invention is described in detail herein, the present invention is not limited thereto. Those skilled in the art may make modifications based on the principles of the present invention. Therefore, all modifications made in accordance with the principles of the present invention should be understood to fall within the protection scope of the present invention.

Claims

1. An aryl indazole ring compound, characterized in that: It includes a compound of formula (I) or a pharmaceutically acceptable salt thereof, Among them, Ar 1 Selected from the following aromatic rings or aromatic ring systems: Ar 2 Selected from the following aromatic rings or aromatic ring systems: Ar 3 Selected from the following aromatic rings or aromatic ring systems:

2. The indazole ring compound according to claim 1, characterized in that: It is selected from any one of the following compounds:

3. A method for preparing an aryl indazole ring compound as claimed in any one of claims 1 to 2, characterized in that: The synthesis steps are as follows: Reactant B1 is added to a dichloromethane solution of reactant A1, and the resulting mixture is stirred at room temperature for 8 hours, then diluted with ethyl acetate and washed with water, then washed with brine, the organic layer is dried over anhydrous sodium sulfate and concentrated, the residue is diluted with dichloromethane and trifluoroacetic acid, the reaction mixture is stirred at room temperature for 4 hours, and then the pH value is adjusted to 12 with saturated sodium bicarbonate; the mixture is extracted with ethyl acetate, washed with water, then washed with brine, the organic layer is dried over sodium sulfate, filtered, concentrated, and eluted with 0-5% by volume methanol in dichloromethane through a silica gel column, chromatographed, and purified to obtain an aryl indazole ring compound.

4. A method for preparing an aryl indazole ring compound as claimed in any one of claims 1 to 2, characterized in that: The synthesis steps are as follows: (1) adding catalyst D1 to a mixture of reactant A2 and reactant B2 in solvent C1, stirring the mixture at 80° C. for 14 h under an argon atmosphere, evaporating the solvent and diluting with ethyl acetate, then washing with water and brine, evaporating the organic phase, and eluting with 10% to 30% by volume ethyl acetate in petroleum ether by silica gel column chromatography, chromatography, and purification to obtain intermediate E1; (2) Add reactant F1 to a dichloromethane solution of intermediate E1; stir the resulting mixture at room temperature for 8 hours, then dilute with ethyl acetate and wash with water, then wash with brine; dry the organic layer over anhydrous sodium sulfate and concentrate, dilute the residue with dichloromethane and trifluoroacetic acid, stir the reaction mixture at room temperature for 4 hours, then adjust the pH to 12 with saturated sodium bicarbonate, extract the mixture with ethyl acetate, wash with water, then wash with brine; dry the organic layer over sodium sulfate, then filter, concentrate, elute with 0-5% by volume methanol in dichloromethane, chromatograph, and purify to obtain an aryl indazole ring compound.

5. A method for preparing an aryl indazole ring compound as claimed in any one of claims 1 to 2, characterized in that: The synthesis steps are as follows: (1) Adding catalyst D2 to a mixture of reactant A3 and reactant B3 in a dry solvent C2, stirring the mixture at 80° C. under an argon atmosphere for 14 h, evaporating the solvent and diluting with ethyl acetate, then washing with water and brine, evaporating the organic phase, eluting with a silica gel column using 10% to 30% by volume ethyl acetate in petroleum ether, chromatography, and purification to obtain intermediate E2; (2) Add reactant F2 to a dichloromethane solution of intermediate E2, stir the resulting mixture at room temperature for 8 hours, then dilute with ethyl acetate and wash with water, then with brine, dry the organic layer over anhydrous sodium sulfate and concentrate, and dilute the residue with dichloromethane and trifluoroacetic acid; stir the reaction mixture at room temperature for 4 hours, then adjust the pH to 12 with saturated sodium bicarbonate, extract the mixture with ethyl acetate, wash with water, then with brine, dry the organic layer with sodium sulfate, then filter, concentrate, and elute with 0-5% by volume methanol in dichloromethane through a silica gel column, chromatograph, and purify to obtain intermediate E3; (3) Adding sodium hydroxide to an anhydrous N,N-dimethylformamide solution of the intermediate E3, stirring the mixture at 0°C, adding an anhydrous N,N-dimethylformamide solution of iodine dropwise, stirring at room temperature for 4 hours, and detecting the reaction end point by LC-MS; after the reaction, the solvent was dried by spin drying, extracted with ethyl acetate, and then washed with water and saturated brine respectively, the organic layer was dried by spin drying, mixed, eluted with 0-30% by volume ethyl acetate in petroleum ether on a silica gel column, chromatographed, and purified to obtain the intermediate E4; (4) Catalyst D3 is added to a dry N,N-dimethylformamide mixture of intermediate E4 and reactant F3, and the mixture is stirred at 80° C. under an argon atmosphere for 14 h. The solvent is evaporated and diluted with ethyl acetate, and then washed with water and brine. The organic phase is evaporated, eluted with 10% to 30% by volume ethyl acetate in petroleum ether, chromatographed, and purified to obtain an aryl indazole ring compound.

6. A pharmaceutical composition comprising one or more therapeutically effective amounts of the aryl indazole ring compound represented by the general formula (I) as claimed in claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

7. Use of one or more aryl indazole ring compounds represented by general formula (I) as claimed in claim 1 or pharmaceutically acceptable salts thereof in drugs for diseases caused by up-regulation of angiogenesis by VEGFR2 kinase activity.

8. The use of the compound as claimed in claim 7 in a drug for a disease caused by up-regulation of angiogenesis by VEGFR2 kinase activity, wherein: The disease includes at least one of anti-tumor therapy or rheumatism such as rheumatoid arthritis, autoimmune disease, and / or The disease includes various inflammatory diseases, such as at least one of arthritis, asthma, and inflammatory bowel disease.

9. Use of one or more aryl indazole ring compounds represented by the general formula (I) as claimed in claim 1 or pharmaceutically acceptable salts thereof in a drug for preventing or treating rheumatoid arthritis by targeting the VEGFR2 / PI3K / AKT pathway to inhibit synovial angiogenesis.

10. The use of the method of claim 9 for inhibiting synovial angiogenesis by targeting the VEGFR2 / PI3K / AKT pathway to prevent or treat rheumatoid arthritis, wherein: The rheumatoid arthritis disease includes at least one of joint involvement, rheumatoid vasculitis, cardiac system involvement, respiratory system involvement, kidney involvement, and blood system problems (such as anemia), pleurisy, pleural effusion, pulmonary arteritis, interstitial lung disease, glomerulonephritis, and tubulointerstitial nephritis.

Citation Information

Patent Citations

  • Novel indazole derivative kinase inhibitors

    CN109942544A

  • Indazole kinase inhibitor and applications thereof

    CN111138426A

  • Kinase inhibitor

    CN113735859A

  • Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use

    CN1374950A

  • Indazol compound for inhibiting protein kinase and medicine composition and their application

    CN1495171A